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Background: Stroke is a major cause of death and disability worldwide. Hypoxia is common after stroke
and is associated with worse outcomes. Oxygen supplementation could prevent hypoxia and secondary
brain damage.
Objectives: (1) To assess whether or not routine low-dose oxygen supplementation in patients with
acute stroke improves outcome compared with no oxygen; and (2) to assess whether or not oxygen
given at night only, when oxygen saturation is most likely to be low, is more effective than
continuous supplementation.
Design: Multicentre, prospective, randomised, open, blinded-end point trial.
Setting: Secondary care hospitals with acute stroke wards.
Participants: Adult stroke patients within 24 hours of hospital admission and 48 hours of stroke onset,
without definite indications for or contraindications to oxygen or a life-threatening condition other
than stroke.
Interventions: Allocated by web-based minimised randomisation to: (1) continuous oxygen: oxygen via
nasal cannula continuously (day and night) for 72 hours after randomisation at a flow rate of 3 l/minute if
baseline oxygen saturation was ≤ 93% or 2 l/minute if > 93%; (2) nocturnal oxygen: oxygen via nasal
cannula overnight (21:00–07:00) for three consecutive nights. The flow rate was the same as the
continuous oxygen group; and (3) control: no routine oxygen supplementation unless required for reasons
other than stroke.
Main outcome measures: Primary outcome: disability assessed by the modified Rankin Scale (mRS) at
3 months by postal questionnaire (participant aware, assessor blinded). Secondary outcomes at 7 days:
neurological improvement, National Institutes of Health Stroke Scale (NIHSS), mortality, and the highest and
lowest oxygen saturations within the first 72 hours. Secondary outcomes at 3, 6, and 12 months: mortality,
independence, current living arrangements, Barthel Index, quality of life (European Quality of Life-5
Dimensions, three levels) and Nottingham Extended Activities of Daily Living scale by postal questionnaire.
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Results: In total, 8003 patients were recruited between 24 April 2008 and 17 June 2013 from
136 hospitals in the UK [continuous, n = 2668; nocturnal, n = 2667; control, n = 2668; mean age 72 years
(standard deviation 13 years); 4398 (55%) males]. All prognostic factors and baseline characteristics were
well matched across the groups. Eighty-two per cent had ischaemic strokes. At baseline the median
Glasgow Coma Scale score was 15 (interquartile range 15–15) and the mean and median NIHSS scores
were 7 and 5 (range 0–34), respectively. The mean oxygen saturation at randomisation was 96.6% in the
continuous and nocturnal oxygen groups and 96.7% in the control group. Primary outcome: oxygen
supplementation did not reduce disability in either the continuous or the nocturnal oxygen groups. The
unadjusted odds ratio for a better outcome (lower mRS) was 0.97 [95% confidence interval (CI) 0.89 to
1.05; p = 0.5] for the combined oxygen groups (both continuous and nocturnal together) (n = 5152) versus
the control (n = 2567) and 1.03 (95% CI 0.93 to 1.13; p = 0.6) for continuous versus nocturnal oxygen.
Secondary outcomes: oxygen supplementation significantly increased oxygen saturation, but did not affect
any of the other secondary outcomes.
Limitations: Severely hypoxic patients were not included.
Conclusions: Routine low-dose oxygen supplementation in stroke patients who are not severely hypoxic is
safe, but does not improve outcome after stroke.
Future work: To investigate the causes of hypoxia and develop methods of prevention.
Trial registration: Current Controlled Trials ISRCTN52416964 and European Union Drug Regulating
Authorities Clinical Trials (EudraCT) number 2006-003479-11.
Funding details: This project was funded by the National Institute for Health Research (NIHR) Research
for Patient Benefit and Health Technology Assessment programmes and will be published in full in
Health Technology Assessment; Vol. 22, No. 14. See the NIHR Journals Library website for further
project information.
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Plain English summary
A lmost one in every six patients dies within the first month of a stroke in the UK. Those who surviveare often left with disability and rely on other people to help them with their day-to-day activities.
Doctors are still trying to find ways of reducing this level of death and disability. During and after a stroke,
blood supply to part of the brain is reduced, leading to a lack of oxygen. This study has looked at whether
or not giving patients oxygen soon after their stroke can prevent further brain damage and reduce death
and disability.
We recruited 8003 patients from 136 hospitals in the UK. Patients included in the study were randomly
assigned to one of three treatment groups: (1) oxygen given continuously for 3 days after their stroke;
(2) oxygen given for three nights; or (3) no oxygen, unless it was needed for other reasons. The hospital
staff then reviewed the patients’ brain function after a week. Patients were sent questionnaires in the post
at 3, 6 and 12 months to see how they were doing.
The results have shown that giving oxygen to stroke patients increased the level of oxygen in the blood,
but did not improve patients’ brain function, level of disability, quality of life or chances of survival.
Oxygen treatment did not improve recovery from the stroke.
This means that it is not necessary to give patients oxygen routinely after a stroke unless needed for
other reasons.
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Scientific summary
Background
The introduction of specialist stroke units has reduced stroke-related mortality and disability. However,
stroke is still the largest cause of complex disability, with half of all survivors requiring help with activities
of daily living.
Mild hypoxia is not normally a problem in healthy adults, but it is common in stroke patients, and may
result in further damage to an already ischaemic brain. Prophylactic oxygen therapy could prevent this
additional deterioration by avoiding hypoxic events. However, oxygen treatment is not without side effects.
There is an associated risk of infection with the therapy and a patient is confined to bed, impeding early
mobilisation and rehabilitation.
Evidence from randomised controlled trials is conflicting, and insufficient to guide clinical practice. This is
reflected in clinical uncertainty and conflicting guidelines based on the same evidence. An adequately
powered study of routine oxygen supplementation (ROS) is needed to provide reliable information on
which recommendations can be based.
Objectives
1. To assess whether or not routine low-dose oxygen supplementation during the first few days following
stroke improves patients’ outcome compared with no oxygen.
2. To assess whether or not oxygen given at night only is more effective than continuous oxygen.
Methods
The Stroke Oxygen Study (SO2S) is a multicentre, prospective, randomised, open, blinded-end point
(PROBE) trial.
Participants were adult patients with a clinical diagnosis of acute stroke, who were within 24 hours of
hospital admission and 48 hours of stroke onset. Patients were not eligible for the trial if they had any
definite indications for, or contraindications to, oxygen treatment, or had another serious life-threatening
condition that was likely to lead to death within the next 12 months.
Patients were recruited by clinicians and research nurses from 136 hospitals across England, Northern
Ireland and Wales. Each hospital had an acute stroke unit. The research team at the recruiting centre
randomised the patients via a computer-generated web-based system. Randomisation included a
minimisation protocol, which allocated participants on a 1 : 1 : 1 basis to one of three trial arms:
1. Continuous oxygen: oxygen via nasal cannula continuously (day and night) for 72 hours after
randomisation. The flow rate was set at 3 l/minute if baseline oxygen saturation was ≤ 93% or
2 l/minute if baseline saturation > 93%.
2. Nocturnal oxygen: oxygen via nasal cannula overnight (21:00–07:00) for three consecutive nights.
The flow rate was set at 3 l/minute if baseline oxygen saturation was ≤ 93% or 2 l/minute if the
baseline saturation was > 93%.
3. Control group: no ROS during the first 72 hours after randomisation unless required for other
clinical reasons.
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Patients’ vital signs including oxygen saturation were monitored at least 6-hourly. Patients who developed
clinical indications for oxygen treatment or needed a higher dose of oxygen than that delivered by the trial
intervention were given additional oxygen, as determined by their treating physicians.
Baseline, randomisation and 1-week follow-up data were collected and entered online into the trial
database by the research team based at the recruiting hospital. Baseline assessment included patient
demographics, date and time of the stroke, oxygen therapy prior to randomisation, existing comorbidities,
Glasgow Coma Scale (GCS), the Six Simple Variables (SSV) outcome prediction tool, the National Institutes
of Health Stroke Scale (NIHSS) and consent details.
Patients were assessed by members of the local research team at week 1, or on the day of discharge,
if sooner. The assessment included neurological function (NIHSS), vital status, adverse events, oxygen
prescriptions for clinical indications in addition to the trial intervention, information on compliance,
physiological variables, details of other treatments including antibiotics and sedatives, results of
computerised tomography or magnetic resonance imaging head scans, the final diagnosis and contact
details for follow-up.
The trial co-ordinating centre sent follow-up questionnaires via post to patients at 3, 6 and 12 months
post randomisation. If the questionnaires were not returned, then patients or their preferred alternative
contacts were telephoned to complete the questionnaire with a data assistant. The questionnaire booklet
contained: the discharge date; current living arrangements; hospital readmissions; the modified Rankin
Scale (mRS); the Barthel Index (BI); the European Quality of Life-5 Dimensions, three levels (EQ-5D-3L) and
the European Quality of Life Visual Analogue Scale (EQ-VAS); the Nottingham Extended Activities of Daily
Living (NEADL) scale; patient-reported outcome measures of sleep, eyesight, speech and memory; and
which trial treatment they remembered receiving.
The primary outcome was disability assessed by the mRS (range from 0 = no disability to 5 = extreme
disability) at 90 days post randomisation. Death was included as a score of 6. Secondary outcomes at day
7 included neurological improvement, NIHSS and mortality, and the lowest and highest oxygen saturations
recorded during the 72-hour treatment period. Long-term outcomes were mortality, the number of
patients alive and independent, the number of patients living at home, the BI, the EQ-5D-3L and EQ-VAS,
and the NEADL, at the 3-, 6- and 12-month time points.
The original sample size calculation of 6000 patients was revised to 8000 patients in October 2012 to give
a greater power to detect an interaction between stroke severity subgroups and the effect of oxygen
compared with control.
Statistical analysis was by intention to treat. The primary outcome of mRS as a measure of disability at
90 days post randomisation was analysed using an ordinal logistic regression model. Analyses adjusted
for age, sex, baseline NIHSS, baseline oxygen saturation and the SSV prognostic index for 6-month
independence were also conducted. To avoid bias due to patients dying before the assessment point,
the worst outcome on each of the scales was used for the analysis. Planned subgroup analyses were
performed for the mRS only, based on a risk stratification approach. The subgroups were based on stroke
severity (NIHSS at baseline), baseline oxygen saturation, oxygen treatment prior to randomisation, time
since stroke onset, final diagnosis, Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification,
GCS, age, comorbidities, thrombolysis and baseline SSV risk score for independence at 6 months.
To estimate the cost-effectiveness and cost–utility of ROS versus no oxygen supplementation, a within-trial
economic evaluation was conducted. Additional analyses also compared all three trial arms. The cost per
additional day of home time gained was calculated for the cost-effectiveness analysis and quality-adjusted
life-years (QALYs) for the cost–utility analysis.
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Results
Between 24 April 2008 and 17 June 2013, 8003 patients were recruited to SO2S. Participants were
randomised to the three trial arms, with 2668 in the control group, 2668 in the continuous oxygen group
and 2667 in the nocturnal (night-time only) oxygen group.
Fully informed consent was given by 6991 (87%) of patients and assent given by a relative, carer or
independent legal representative for 1012 (13%) patients. In total, over the 12-month participation, 89, 81
and 81 patients withdrew from the continuous oxygen, nocturnal oxygen and control groups, respectively.
Baseline characteristics were well balanced across the three trial arms. The overall mean age was 72 years
[standard deviation (SD) 13 years] and 4398 (55%) patients were male. Of the 8003 patients, 7332 (92%)
were independent in activities of daily living prior to their stroke, and this was equally distributed across
the three groups. Medical history and comorbidities were also well matched, with ischaemic heart disease
(n = 1602, 20%), heart failure (n = 657, 8%), atrial fibrillation (n = 1995, 25%) and chronic lung
conditions (n = 812, 10%) recorded in each group. The median GCS score was 15 [interquartile range
(IQR) 15–15] and the mean and median NIHSS scores were 7 and 5 (range 0–34), respectively. Ischaemic
stroke was the final diagnosis in 82% of patients (n = 6555), followed by primary intracerebral
haemorrhage in 7% (n = 588), transient ischaemic attack in 2% (n = 168), and a non-stroke diagnosis
in 4% (n = 292). This information was unavailable for 106 patients (1%). The mean baseline oxygen
saturation was 96.6% in the continuous (SD 1.7) and nocturnal oxygen (SD 1.6) groups and 96.7%
(SD 1.7) in the control group. Oxygen therapy prior to randomisation was recorded in 20% of patients.
In the continuous oxygen arm 2158 (81%) patients completed the 72 hours of the trial intervention and
433 (16%) did not. Treatment adherence was similar in the nocturnal oxygen arm, with 2225 (83%)
patients completing the three nights of oxygen therapy and 361 (14%) not doing so. Discharge from
hospital was the most common reason for a patient not receiving the complete trial intervention. In the
control group 2229 (84%) patients did not receive any ROS for the treatment of stroke. There were
23 (1%) patients who received oxygen therapy in the control group. This information was missing for
406 (15%) participants.
Routine oxygen supplementation did not improve functional outcome at 3 months compared with the
control group. No statistically significant difference was recorded between the continuous oxygen and
the nocturnal oxygen arms. The unadjusted odds ratio (OR) for a better outcome (lower mRS) was 0.97
[95% confidence interval (CI) 0.89 to 1.05; p = 0.5] for oxygen (continuous and nocturnal combined)
compared with the control, and 1.03 (95% CI 0.93 to 1.13; p = 0.6) for continuous compared with
nocturnal oxygen. The adjusted analyses yielded very similar results. For combined oxygen compared with
control the OR was 0.97 (95% CI 0.89 to 1.06; p = 0.5) and comparing the two oxygen interventions the
OR was 1.01 (95% CI 0.92 to 1.12; p = 0.8). No subgroups were identified that benefited from oxygen
supplementation when the study population was divided based on the previously described parameters.
Sensitivity analyses based on multiple imputation and an adherers-only analysis, aimed at investigating
potential bias resulting from missing data, also revealed similar outcomes. Additional sensitivity analyses
represented best- and worst-case scenarios, to set maximum plausible bounds for the effect of missing data.
Neurological improvement at week 1 did not differ between the three trial groups (median NIHSS score,
2; IQR, 1–6). Exploratory analyses of the data collected at the week 1 review did not show any appreciable
differences for indicators of stress (highest heart rate, blood pressure and need for sedation), or for
indicators of infection (antibiotic treatment and highest temperature). Highest and lowest oxygen
saturations increased by 0.8% and 0.9%, respectively, in the continuous oxygen group when compared
with the control group and by 0.5% and 0.4%, respectively, when compared with the nocturnal group
(p < 0.001 for all comparisons). Significantly more participants in the combined oxygen group than in the
control group required oxygen for clinical reasons outside the trial intervention (p = 0.0008). This was also
the case in the continuous versus nocturnal oxygen groups (p = 0.03).
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Long-term functional outcome did not improve with oxygen therapy at any of the 3-, 6- and 12-month
follow-up time points. The number of patients who were alive and independent and back in their own
homes, the ability to perform basic activities of daily living (BI) or the Nottingham Extended Activities of
Daily Living scale score and quality of life (EQ-5D-3L) at 90, 180 and 365 days were not increased by ROS.
Mortality at 90 days was similar in the oxygen (both groups combined) and control group (hazard ratio
0.97, 99% CI 0.78 to 1.21; p = 0.8), and for continuous oxygen versus oxygen at night only (hazard ratio
1.15, 99% CI 0.90 to 1.48; p = 0.1). Neither patient-reported outcome measures nor the rate of
readmission to hospital was improved by the trial interventions at any of the follow-up assessments.
The number of serious adverse events did not differ at any of the three follow-up time points between the
three trial arms.
The health economics analysis results were in line with the clinical findings. The trial treatment was
associated with increased costs, as expected. Patients did not return home more quickly or experience
more QALYs with either of the oxygen treatments. The cost-effectiveness analysis demonstrated a low
probability of cost-effectiveness (31%) at £20,000/QALY.
Conclusions
The results of the study have shown that low-dose oxygen supplementation in stroke patients who are not
severely hypoxic does not confer any benefits either for the whole population or for any subgroups. This
lack of benefit is consistent across all outcomes and for all time points up to 1 year. It also did not matter
if the oxygen was given continuously or at night-time only. Future research should investigate the causes
of hypoxia and explore ways of preventing desaturations in stroke patients.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN52416964 and European Union Drug Regulating
Authorities Clinical Trials (EudraCT) number 2006-003479-11.
Funding
This project was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit
and Health Technology Assessment programmes and will be published in full in Health Technology
Assessment; Vol. 22, No. 14. See the NIHR Journals Library website for further project information.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
Chapter 1 Introduction
S troke is the third most common cause of death worldwide.1 With approximately 110,000 strokes perannum in England, it accounts for 11% of deaths.2 Stroke mortality is cited as 20–30% within 1 month
in the 2007 National Stroke Audit report.2 More recent data suggest lower rates: between 14% and 17%
for the UK3 and 14.5% in the USA.4 Improvements in processes of care have significantly contributed to
this reduction.4 However, half of all stroke survivors are left dependent on others for everyday activities,2
making stroke the largest cause of complex disability.5 Care on specialist stroke units has been shown to
reduce death and disability significantly.6 It does, however, remain unclear which aspects of stroke care are
crucial for improving outcome. Prevention and treatment of hypoxia could potentially be one of the
reasons for better outcome with specialist stroke care.
Scientific background
Prevalence of hypoxia and effects on outcome
Mild hypoxia is common in stroke patients and may have significant adverse effects on the ischaemic
brain.7 Hypoxia with oxygen saturations falling below 92% has been observed in 24% of continuously
monitored stroke patients within the first 24 hours of symptom onset.8 While healthy adults with normal
cerebral circulation can compensate for mild hypoxia by an increase in cerebral blood flow,9 this is not
possible in the already ischaemic brain after stroke.10–13 Hypoxaemia with oxygen saturations falling below
90% in the first few hours after hospital admission is associated with a doubling of mortality14 and a
trebling of the rate of institutionalisation.15 Patients on a stroke unit are more likely to receive oxygen than
patients on a non-specialised general ward16 and less likely to be hypoxic.17 An observational study of
processes of care has shown that hypoxia increases the risk of an adverse outcome fivefold if only some of
the hypoxic episodes are treated with oxygen, but has no adverse effect on outcome if all episodes of
hypoxia are treated with oxygen.15 Prophylactic oxygen treatment could prevent hypoxia and secondary
neurological deterioration.
Potential adverse effects of oxygen treatment
However, oxygen treatment is not without side effects.18 It impedes early mobilisation and could pose an
infection risk. There is evidence from animal models and in vitro studies that oxygen encourages the
formation of toxic free radicals, leading to further damage to the ischaemic brain,19–22 especially during
reperfusion. Marked changes in adenosine triphosphate and related energy metabolites develop quickly
in response to acute ischaemia and tissue hypoxia. These alterations are only partially reversed on
reperfusion despite improved oxygen delivery. Ischaemia-induced decreases in the mitochondrial capacity
for respiration result in reduced oxygen consumption and further increase free radical generation during
reperfusion.23 Oxidative stress has also been implicated in the activation of cell signalling pathways, which
leads to apoptosis and neuronal cell death.24,25 While much research points towards adverse effects of
hyperoxia in the ischaemic brain, there is also evidence to support the notion that therapy-induced eubaric
hyperoxia may be neuroprotective.19,20,26,27 Routine oxygen supplementation (ROS) for acute myocardial
infarction has been abandoned after a clinical trial showed no benefit and potential harm.28
Randomised controlled trials of oxygen treatment after acute stroke
Evidence from randomised controlled trials of oxygen supplementation after acute stroke is conflicting and
insufficient to guide clinical practice. A quasi-randomised study of oxygen supplementation for acute stroke
by Rønning and Guldvog29 has shown that routine oxygen treatment in unselected stroke patients does not
reduce morbidity and mortality. Subgroup analyses suggested that patients with severe strokes were more
likely to benefit than those with mild strokes, but the study size was too small to define patients who are
likely to derive benefit with certainty.29 A very small (n = 16) study of high-flow oxygen treatment after
acute stroke showed that cerebral blood volume and blood flow within ischaemic regions improved
with hyperoxia. By 24 hours, magnetic resonance imaging of the brain showed reperfusion in 50% of
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hyperoxia-treated patients compared with 17% of control patients (p = 0.06) but no long-term clinical
benefit at 3 months.30 In the Stroke Oxygen Pilot Study (ISRCTN 12362720), the flow rate of oxygen was
lower (2 or 3 l/minute dependent on baseline oxygen saturation) and treatment was continued for longer
(72 hours). Neurological recovery at 1 week was better in the oxygen group than in the control group.31
While there was no difference in the mRS at 6 months, there was a trend for better outcome with oxygen
after adjustment for differences in baseline stroke severity and prognostic factors.32 In contrast to the earlier
study by Rønning and Guldvog,29 oxygen was as effective in mild as in severe strokes. These results are
promising, but need to be confirmed in a larger study.
Recommendations for oxygen treatment in national and international
clinical guidelines
Clinical guidelines for oxygen supplementation after stroke are not based on evidence from randomised
clinical trials, and have changed over time without obvious reason. The European Stroke Organization (2008)33
stated that ROS to all stroke patients had not been shown to be effective, but that adequate oxygenation
was important, and that oxygenation can be improved by giving oxygen at a rate of > 2 l/minute (no target
saturation or supporting evidence given). In 2003, the American Stroke Association Guideline34 recommended
keeping the oxygen saturation at or above 95%. The 2005 update25 of the guideline made no change to the
recommendations. In 2007, the advice was revised to say that oxygen saturation should be maintained at or
above 92%,35 but in 2013 the Association reverted to recommending maintenance of an oxygen saturation
at or above 95%.36 In the UK, the National Clinical Guideline for the management of people with stroke
recommended keeping oxygen saturation within normal limits in 2005 and in 200837,38 and in 201239 it
specified that this means maintaining an oxygen saturation ≥ 95%. None of the recommendations is based
on evidence from controlled clinical trials. A survey of British stroke physicians showed that there is uncertainty
among physicians treating patients with stroke about which treatment approach to take, and when to
give oxygen.40
Rationale for the Stroke Oxygen Study
Hypoxia is common after acute stroke and is associated with worse outcomes. Prevention of hypoxia
could avert secondary brain damage and improve recovery. Evidence from randomised controlled trials is
conflicting, and insufficient to guide clinical practice. This is reflected in clinical uncertainty and conflicting
guidelines based on the same evidence. An adequately powered study of ROS is needed to provide reliable
information on which recommendations can be based.
Aims
The aim of the Stroke Oxygen Study (SO2S) is, first, to establish whether or not ROS will improve outcome
after stroke and, second, to determine whether or not oxygen given at night only is more effective than
oxygen given continuously.
Rationale for the fixed dose oxygen regimen used in the Stroke Oxygen Study
A fixed dosage scheme was chosen to keep the design of the study as simple as possible, so that any
recommendations resulting from the study outcome can be carried out in day-to-day clinical practice.
Rønning and Guldvog29 have shown that giving oxygen at a rate of 3 l/minute to all stroke patients during
the first 24 hours after hospital admission does not improve overall outcome. They did not report baseline
oxygen saturation, or changes in saturation on treatment. It is therefore possible that some patients
were undertreated, and that others achieved too high oxygen levels, leading to an increase in free
radical generation in the ischaemic penumbra. There were no other data from clinical studies to inform
recommendations for the dose of oxygen to give for routine supplementation at the time the study was
designed. The European Stroke Organization suggested a dose of 2–4 l/minute and the American Stroke
INTRODUCTION
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Association Guideline recommended keeping the oxygen saturation at or above 95%,34,41,42 but these
recommendations were not based on evidence from controlled clinical trials. In the absence of data
to the contrary, it was reasonable to assume that treatment should restore oxygen saturation to the
normal range.
Normal oxygen saturation in adults is 95–98.5%,43 in healthy older individuals it is reported to be lower,
at 95% [standard deviation (SD) 2.5%].44 Oxygen saturation in stroke patients who are normoxic at
recruitment is about 1% lower than that of age-matched community control patients.45 We have
conducted a dose titration study for oxygen after acute stroke and found that 2 l/minute oxygen by nasal
cannula increases oxygen saturation by 2% and 3 l/minute by 3%.46 We also found that oxygen masks
were less likely to be tolerated than nasal cannulae, leading to poorer treatment compliance with the
former. For this study, we therefore decided to give oxygen by nasal cannula. A dosage regimen of
3 l/minute in individuals with a baseline oxygen saturation of ≤ 93% and 2 l/minute in individuals with a
baseline saturation > 93% was therefore considered likely to prevent hypoxia without increasing oxygen
saturation beyond the upper limit of the normal range.
Rationale for giving routine oxygen supplementation at night only
Patients are more likely to be hypoxic at night
The mean nocturnal oxygen saturation is about 1% lower than awake oxygen saturation in both stroke
patients and control patients.45 This study has also shown that a quarter of patients who are normoxic in
the day have significant hypoxia during the night. About 60–70% of stroke patients suffer from sleep
apnoea early after stroke.47–49
The development of hypoxia is more likely to be missed at night
It is more difficult to observe patients in the darkened room, and, unless there are reasons to suspect the
patient is unwell, nurses do not usually wake the patient for routine observations. The development of
hypoxia is therefore more likely to be missed at night.
Nocturnal hypoxaemia is more likely to lead to brain tissue hypoxia at night
A study in healthy volunteers has shown that hypoxaemia leads to a compensatory increase in cerebral
blood flow during wakefulness, but not during sleep, and is therefore more likely to result in brain tissue
hypoxia at night.50
Nocturnal oxygen supplementation does not interfere with the patient’s
daytime mobility
Early mobilisation is an important aspect determining good outcome.16 Patients who are attached to
monitoring equipment, or to oxygen supplementation, are less likely to be mobilised than patients not
attached to such equipment.
Giving routine oxygen at night only may prevent a significant number of otherwise undetected episodes of
hypoxia without interfering with the patient’s daytime rehabilitation.
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Chapter 2 Methods
Trial design
The Stroke Oxygen Study is a multicentre, prospective, randomised, open, blinded-end point (PROBE) trial.
For this controlled, single-blind, parallel group trial patients were randomised in a 1 : 1 : 1 ratio to one of
three study arms:
1. continuous oxygen supplementation
2. nocturnal oxygen supplementation only
3. no ROS, unless required for clinical reasons other than stroke.
Both the Stroke Oxygen Study protocol and the statistical analysis plan have been published in an
open-access journal.51,52
Hypothesis
The main hypothesis was that fixed low-dose oxygen treatment during the first 3 days after an acute
stroke improves outcome compared with no oxygen.
The secondary hypothesis was that restricting oxygen supplementation to night-time only is more effective
than continuous supplementation.
Participants
Recruitment
Patients were recruited by research nurses and clinicians from 136 hospitals (secondary care) across
England, Northern Ireland and Wales (see Appendix 1 for a list of recruiting centres). All recruiting
hospitals had acute stroke units, were able to carry out the required observations four times a day and had
a stroke-trained principal investigator. Screening, baseline, randomisation and 1-week follow-up data were
collected and entered online into the trial database by the research staff based in the local hospital.
Inclusion criteria
l Adult patients (aged ≥ 18 years) with clinical diagnosis of acute stroke.
l Within 24 hours of hospital admission.
l Within 48 hours of stroke onset.
Exclusion criteria
l Definite indication or contraindication to oxygen treatment at a rate of 2–3 l/minute.
l Stroke not the main clinical problem or patient has another serious life-threatening illness likely to lead
to death within the next 12 months.
Consent
Fully informed consent was sought from all research participants. Research nurses or clinicians explained the
study to potential participants, who were also given a patient information sheet explaining the trial. Owing to
the acute nature of stroke and the intervention being tested, there was not a 24-hour consideration period
between receiving the information and taking informed consent. In patients who were unable to give fully
informed consent, assent was sought from either the patient’s next of kin or from an independent physician.
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Fully informed consent was obtained in patients who regained capacity during the first week following
randomisation.
Interventions
Patients were randomised to one of the following three groups:
l Continuous oxygen: oxygen via nasal cannula continuously (day and night) for 72 hours after
randomisation. The flow rate was set at 3 l/minute if baseline oxygen saturation was ≤ 93% or
2 l/minute if baseline saturation > 93%.
l Nocturnal oxygen: oxygen via nasal cannula overnight (21:00–07:00) for three consecutive nights.
The flow rate was set at 3 l/minute if baseline oxygen saturation was ≤ 93% or 2 l/minute if baseline
saturation > 93%.
l Control group: no ROS during the first 72 hours after randomisation unless required for other
clinical reasons.
The oxygen used for the trial was supplied by the hospital through either wall-mounted sockets or portable
or stationary oxygen bottles, depending on local practice.
Follow-up
Patients were followed up at 1 week by research staff at the recruiting hospital, and then at 3, 6 and
12 months via a postal questionnaire from the trial co-ordinating centre (Figure 1). The case report form is
presented in Appendix 2.
Screening, informed consent/assent and baseline data collection
Randomisation
Safety rep
o
rtin
g
Follow-up: 1 week – by recruiting hospital research staff
Follow-up: 3 months – postal questionnaire or by telephone
Follow-up: 6 months – postal questionnaire or by telephone
Follow-up: 12 months – postal questionnaire or by telephone
Nocturnal 
oxygen
Continuous 
oxygen
No oxygen
FIGURE 1 Trial design.
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Assessments
See Table 1 for a summary of patient assessments and timings.
TABLE 1 Summary of patient assessments
Outcome measure Screening Baseline Week 1 3 months 6 months 12 months
Eligibility ✓
Demographics ✓
Glasgow Coma Scale ✓
Medical history ✓
Oxygen treatment prior to randomisation ✓
Prognostic factors (SSV) ✓
NIHSS (neurological function) ✓ ✓
Antibiotics, antipsychotics and sedatives
during week 1
✓
Highest blood pressure and highest heart
rate during first 72 hours
✓
Oxygen saturation during first 72 hours ✓
Compliance with oxygen/control treatment ✓
CT/MRI diagnosis ✓
Final diagnosis ✓
Date of discharge (when appropriate) ✓ ✓ ✓ ✓
Discharge locationa ✓
TOAST classification ✓
Modified Rankin Scale (disability) ✓b ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓
Living arrangements ✓ ✓ ✓
Hospital readmissions ✓ ✓ ✓
Barthel Index (activities of daily living) ✓ ✓ ✓
EQ-5D-3L (quality of life) ✓ ✓ ✓
NEADL ✓ ✓ ✓
Patient-reported outcome measures
(memory, sleep, eyesight and speech)
✓ ✓ ✓
Participants’ awareness of trial allocation ✓ ✓ ✓
Who completed the follow-up
questionnaire
✓ ✓ ✓
Co-recruitment with other trials ✓ ✓ ✓ ✓
CT, computerised tomography; EQ-5D-3L, European Quality of Life-5 Dimensions, three levels; MRI, magnetic resonance
imaging; NEADL, Nottingham Extended Activities of Daily Living scale; NIHSS, National Institutes of Health Stroke Scale;
SSV, Six Simple Variables; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
a Discharge location recorded in 125 patients.
b Modified Rankin scale only recorded in 267 patients.
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Baseline assessment
This was done by the research team randomising the patient, and was either entered online for patients
randomised via the web or sent to the trial centre by fax for patients randomised via telephone. The initial
assessment included baseline demographics, date and time of the event, whether or not the patient had
been given oxygen in the ambulance or in the emergency department, and how much, comorbidities
[chronic obstructive pulmonary disease, other chronic lung problems, heart failure (congestive cardiac
failure), ischaemic heart disease, and atrial fibrillation], the Glasgow Coma Scale (GCS) score,53 score on
the Six Simple Variables (SSV) outcome predictor tool,54 the National Institutes of Health Stroke Scale
(NIHSS) score,55,56 the type of consent (by patient or legal representative) and the date and time
of randomisation.
Week 1 assessment
The week 1 assessment was performed by a member of the local research team trained in the assessment
tools at 7 days (± 1 day) after enrolment. In patients who were discharged before the end of 1 week, or
who could not be followed at 7 days, the assessment was conducted at discharge. Data were entered
online or sent to the trial centre via fax. The week 1 assessment included neurological function (NIHSS),
vital status, adverse events, whether or not the patient was prescribed oxygen for clinical indications during
the first 72 hours, information on compliance with the treatment, details of other treatments (antibiotics
during week 1, thrombolysis, sedatives or antipsychotics), physiological variables (highest heart rate, highest
systolic and diastolic blood pressure, highest and lowest oxygen saturation during the first 72 hours, and
the highest temperature during week 1), the result of the computerised tomography (CT) or magnetic
resonance imaging head scan (cerebral infarct/primary intracerebral haemorrhage/subdural haemorrhage/
brain tumour/head scan not performed/other), the final diagnosis [ischaemic stroke/transient ischaemic
attack (TIA)/primary intracerebral haemorrhage/cerebrovascular accident (CVA) without CT confirmation of
aetiology/other], and the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of stroke
aetiology.57 Compliance was assessed by asking whether or not oxygen was prescribed on the drug chart,
whether or not it was signed, and whether or not it was stopped before the end of 72 hours. After an
amendment of the case report form [version 1, amendment 3 (30 August 2009)], additional details were
recorded for the final 4143 patients. These included a more in-depth assessment of compliance with a
record of oxygen saturation at 06:00, 12:00 and 00:00, whether or not oxygen treatment was in place
at 06:00 and 00:00; whether or not the patient had been enrolled into another study, and which, the
pre-stroke modified Rankin Scale (mRS) and the European Quality of Life-5 Dimensions, three levels
(EQ-5D-3L), whether or not this was reported by the patient or a relative, discharge destination (if
discharged), and whether or not a new brain haemorrhage was identified on a second CT of the head
(if conducted).
Three-, 6- and 12-month assessments
The 3-, 6- and 12-month follow-up assessments were performed centrally by the Stroke Oxygen Study
team. Following a call to the participant’s general practitioner to confirm that the participant was alive
and the contact details were the same as those on the trial database, postal questionnaires were sent
to all participants at 3, 6 and 12 months post randomisation. The questionnaires contained the
discharge date, the mRS,58 the Barthel Index (BI),59 the EQ-5D-3L and the EQ-VAS,60–62 the Nottingham
Extended Activities of Daily Living scale (NEADL),63 questions regarding current abode, whether or not
the patient had been readmitted to hospital since the stroke, patient-reported outcome measures
(sleep, speech and memory), and a question on whether or not they remembered which treatment
they were randomised to. If the questionnaire was not returned within a few weeks, a data assistant
at the trial co-ordinating centre telephoned the patient and completed the questionnaire over the
telephone with either the patient or a relative/carer. See Table 1 for a summary of all patient
assessments and timings.
METHODS
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Outcomes
Primary outcome
The primary outcome measure was disability assessed by the mRS at 90 days post randomisation.58,64
The mRS is an ordinal scale that ranges from 0 for a patient with no disability to 5 for extreme disability.
Death was included in the scale as a score of 6.
Secondary outcome measures at 1 week
The number of patients with neurological improvement (≥ 4-point decrease from baseline in the NIHSS
score or a value of 0 at day 7),55,56 NIHSS score, mortality, the lowest and highest oxygen saturation during
the 72-hour treatment period and the number of patients whose oxygen saturation fell below 90% were
all secondary outcome measures.
Secondary outcome measures at 3, 6 and 12 months
Mortality, the number of patients alive and independent (mRS score of ≤ 2), the number of patients living
at home, the BI of activities of daily living, quality of life EQ-5D-3L and European Quality of Life Visual
Analogue Scale (EQ-VAS) and the NEADL index were all secondary outcome measures for 3-, 6- and
12-month time points.
Sample size
The original sample size calculation of 6000 patients was based on a mean mRS score of 3.51 (SD 2.03).
These values came from the first 200 patients in the Stroke Oxygen Pilot Study.32 A 5% dropout rate
was assumed, along with 5% missing outcome data, giving a total of 10% lost to follow-up. The sample
size of 6000 patients provided 90% power to detect small (0.2 mRS point) differences between ROS
(continuous and nocturnal groups combined) and no oxygen (control group) at a p-value of ≤ 0.01 and
90% power at a p-value of ≤ 0.05 to detect small (0.2 mRS point) differences between continuous
and nocturnal oxygen supplementation.
The sample size calculation was revised in October 2012 without any knowledge of interim results.
Recalculation was conducted using ordinal methods to match with the Statistical Analysis Plan. The study
size was subsequently consequently revised to 8000 patients. Protocol version 2 amendment 4 (18 October
2012) gave greater power to investigate any differential effectiveness of oxygen compared with control
within subgroups, in particular those with more severe disease.
Randomisation and allocation
Patients were randomised via a computer-generated web-based randomisation system at the Birmingham
Clinical Trials Unit. Randomisation was performed using minimisation with the following factors: the SSV
prognostic index for independent survival at 6 months (cut-off points ≤ 0.1, > 0.1 to ≤ 0.35, > 0.35 to
≤ 0.70 and > 0.70), oxygen treatment before randomisation (yes, no and unknown), baseline oxygen
saturation on air (< 95% and ≥ 95%), and time since stroke onset (≤ 3 hours, > 3 to ≤ 6 hours, > 6 to
≤ 12 hours, > 12 to ≤ 24 hours and > 24 hours). Study centre was not included as a minimisation variable
to avoid potentially high rates of allocation prediction and selection bias. Patients were randomised via a
web-based randomisation program at the level of the individual on a 1 : 1 : 1 basis to either no oxygen,
nocturnal oxygen or continuous oxygen. Enrolment and intervention assignment was performed by the
clinical team at the recruiting centre.
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Blinding
This study was open, as placebo treatment (room air) would have similar side effects as the active
treatment (e.g. infection and immobilisation), but no potential benefit, and could thus bias the data in
favour of the treatment group. The main outcomes were ascertained at 3 months by central follow-up,
which ensured that the assessor was blind to the intervention. Assessment was by postal questionnaire,
or, when participants did not respond to the letters, by telephone interview. It is possible that the patients
completing the follow-up questionnaire or responding to the interview questions may have had some
recollection of being treated with oxygen or not. Patients were asked to state on the questionnaire if they
remembered/could guess which treatment group they were in. This was compared with the actual
allocation to quantify potential bias.
Statistical methods
The analysis is by intention to treat. The primary outcome measure is disability (mRS) at 90 days after
randomisation. The mRS is an ordinal scale ranging from 0 (no disability) to 5 (extreme disability).
Patients who were classified as dead at the 3 months were allocated a mRS score of 6, thus creating
a 0 to 6 scale.
The mRS was analysed using an ordinal logistic regression model. Both an unadjusted (primary) and
adjusted (secondary) analysis were performed. For each outcome variable, the unadjusted analysis is
the primary analysis and the covariate-adjusted analysis is the secondary analysis. Adjusted analyses
incorporated the following covariates: age, sex, baseline NIHSS score, baseline oxygen saturation and the
SSV prognostic index for 6-month independence. For analysis of mortality data, the prognostic index for
30-day survival was used in place of that for 6-month independence.
Participants who died before the assessment point did not have data for NIHSS, BI, EQ-5D and EQ-VAS, or
NEADL. To avoid bias in favour of the treatment arm with higher mortality (should this be the case), death
was included in the analysis of the NIHSS, BI, EQ-VAS and the NEADL as the worst outcome on the scale.65
For continuous outcomes means and SDs or medians and interquartile ranges (IQRs) are reported, as
appropriate. Unadjusted analyses used an unrelated t-test, with the mean difference between treatments
and corresponding confidence interval (CI) reported. In the event of major deviations from the assumptions
of the t-test, an appropriate alternative analysis was used. The adjusted analysis used analysis of covariance
methods, with the covariates specified earlier included in the analysis.
For dichotomous outcomes, percentages were compared across the treatment comparisons using a
chi-squared test (unadjusted analysis). The adjusted analysis of dichotomous outcomes used binary logistic
regression with the covariates listed earlier. Odds ratios (ORs) and CIs are reported. The number needed to
be treated was to be calculated, if significant effects were to be seen.66 As there were no differences, this
was not done.
For ordinal secondary outcomes, the analyses described for the mRS were applied.
Data at 6 and 12 months
The longer-term follow-up data at 6 and 12 months were analysed at each time point using the same
methods as those listed previously. In addition, analyses were performed across 3-, 6- and 12-month time
points using a longitudinal repeated measures analysis, in this case linear mixed models.67
The treatment effect was initially assumed to be constant over time; further analyses were carried out to
investigate the effects of including time and a treatment-by-time interaction in the models.
METHODS
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Mortality was analysed using log-rank methods (unadjusted analysis) with Kaplan–Meier plots. The
adjusted analysis used Cox regression methods, including the covariates listed above. In the covariates,
the prognostic index for 30-day survival replaced that for independence at 6 months. The proportional
hazards assumption associated with the Cox regression was tested via Schoenfeld residuals. Hazard ratios
and 95% CIs are reported for both the unadjusted and adjusted analyses.
Planned subgroup analyses
These were performed in respect of the primary outcome measure only, based on a risk-stratification
approach.68 The subgroups comprise:
l NIHSS score at baseline as indicator of stroke severity (0–4, 5–9, 10–14, 15–20 and > 20)
l baseline % oxygen (O2) saturation (< 94%, 94–94.9%, 95–97% and > 97%)
l treatment with O2 prior to randomisation (yes/no)
l time in hours since onset of stroke (< 4 hours, 4 to < 7 hours, 7 to < 13 hours, 13 to < 24 hours and
≥ 24 hours)
l final diagnosis (haemorrhage, infarct, TIA and other)
l TOAST classification of infarct aetiology
l GCS score (motor plus eye score:< 10 and 10)
l age (< 50 years, 50–80 years and > 80 years)
l history of chronic obstructive airway disease or asthma (yes/no)
l history of heart failure (yes/no)
l thrombolysed (yes/no)
l baseline SSV risk score for independence at 6 months (≤ 0.1, > 0.1 to 0.35, > 0.35 to 0.7 and > 0.7).
These subgroup effects were analysed by means of an interaction term;69 however, pairwise hypothesis
tests between the levels of the subgroup factor were not performed owing to the likely low level of
statistical power. Subgroup-specific estimates are reported descriptively with 99% CIs and displayed
graphically on a forest plot.
Health economics methods
Overview
A within-trial economic evaluation was conducted alongside the clinical trial in order to estimate the
cost-effectiveness and cost–utility of ROS compared with no oxygen supplementation (no ROS) after
stroke, over 12 months’ follow-up. Further analysis compared all three trial arms: (1) no ROS, (2) nocturnal
oxygen for three nights, and (3) 72 hours’ continuous oxygen. The base-case economic evaluation
adopted an NHS/Personal Social Services perspective. The cost-effectiveness analysis calculated the cost
per additional day of home time gained, using information on length of stay in hospital and discharge
destination. The cost–utility analysis (CUA) used quality-adjusted life-years (QALYs) as the benefit measure,
in which QALYs take into account the survival and quality of life of an individual. The reporting of this
analysis follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).70
Health outcomes
Information on length of stay in hospital due to stroke, discharge destination and any readmissions to
hospital were used to calculate the number of home time days per patient over a 12-month period. Home
time has been previously used as an outcome measure in other stroke trials.71,72 When data on actual
discharge location were not available, the response to a question regarding place of residence at 3 months
was used as a proxy for the discharge location. Discharge to institutional care (nursing home or residential
care) was not counted as home time. The actual length of stay for readmissions was not available for all
patients in the trial; therefore, a sample of 100 readmissions was analysed to determine the mean length
of stay for a readmission. This value was attached to all patients who had a readmission, and used in the
calculation of home time gained. Although the intention was to calculate home time gained in the first
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90 days, as there were poor data on the date of readmission, home time gained was calculated over the full
12 months.
The EQ-5D-3L questionnaire73 was completed at 3, 6 and 12 months, and when a patient had died during
the 12 months, the date of death was noted and a value of zero (equivalent to dead) was assumed from the
date of death. EQ-5D-3L data were not collected at baseline, as it was not possible for a patient admitted
for a stroke to fill in a health-related quality of life questionnaire. Therefore, we used a previously published
method74 and assumed that the EQ-5D-3L score for all patients at baseline was zero, and the change in
quality of life between baseline and 3 months was linear. An alternative method for baseline EQ-5D-3L score
was used in a sensitivity analysis by assuming that the baseline quality of life was equal to the EQ-5D-3L
value at 3 months. Quality of life estimates were derived from EQ-5D-3L responses provided by patients at
each time point by applying the standard UK tariff values.75 These estimates were then used to calculate
total QALYs over 12 months for every individual in the study, using the area under the curve approach.
Resource use and costs
The costs included in the analysis related to oxygen administration as prescribed by the trial, additional
oxygen required for other clinical reasons, length of stay in hospital, readmission to hospital and long-term
care on discharge from hospital. All costs in the analysis were in UK pounds (£), based on a price year
of 2013–14. Unit costs were obtained from published standard sources of costs for NHS procedures,76 staff
costs77 and previously published research (Table 2). Health and Community Health Services pay and price
indices were used to inflate costs, when appropriate.77 Unit costs are listed in Table 2.
For the purposes of estimating the cost of oxygen administration as prescribed in the trial, it was assumed
that, once a patient was allocated to a treatment arm, costs of treatment were incurred. The cost of
oxygen administration was adjusted for those patients for whom continuous oxygen was prescribed for
clinical reasons outside the trial treatment, as described in Table 3. Information on resources required
for oxygen administration, including any additional staff time and equipment required for each treatment
group, was collected prospectively during the trial using a short questionnaire filled in by a representative
in 24 participating hospitals (see Appendix 3). The cost of each resource type was calculated in order to
determine the cost of oxygen supplementation per trial arm (Table 4). All institutions included in the trial
were assumed to have the same expertise and to have followed similar protocols in the management
of patients.
Patients in the trial had a stroke, TIA or a stroke mimic. For a stroke, a NHS reference cost for a CVA was
assumed, as the majority of strokes were ischaemic. As there were five different categories for CVA, taking
into account the number of complications and comorbidities, the median was calculated for the cost of a
non-elective long stay, cost of an excess bed-day and average length of stay. These values were then
adjusted for the length of stay in hospital for each patient, either adding or subtracting a bed-day cost for
length of stay under or over the median length of stay. For patients who had a TIA or stroke mimic, the NHS
reference cost for a TIA was assumed, using the same methodology as for CVA to adjust for length of stay.
As full data on the details and length of stay of any non-elective readmissions during the 12 months were
not available, the overall average cost of a non-elective admission (for all categories) was used.
Patient-level resource use on long-term care beyond the initial hospital admission was unavailable;
however, the responses to the mRS provided information on the level of dependence. Patients were
categorised as independent (mRS score of 0–2) or dependent (mRS score of 3–5) using data from the
3-month questionnaire. The annual cost of independent and dependent stroke after discharge from
hospital was obtained from Sandercock et al.79 and updated to 2013/14 costs. This annual cost was
then adjusted to take into account the time not in hospital over the 12-month period.
For the purpose of the analysis, the costs of acute stay in hospital and long-term care were not included
in the cost-effectiveness analysis to avoid double counting, as the measure of outcome was home
time gained.
METHODS
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TABLE 2 Health-care resource use unit costs
Health-care resource Unit cost (£) Source
Oxygen supplementation
Staff costs (per hour)
Sister/charge nurse 51 Curtis, 201477
Registered nurse 34
Student/research nurse 21
Registrar 40
Consultant 101
Physiotherapist 33
Allied professional 23
Housekeeping 26
Equipment cost (per item)
Oxygen tubing 6.35 University Hospitals of North Midlands NHS Trust
supplies document, 201578
Portable oxygen cylinder 20.52
Nasal tubes 4.85
Oxygen mask 4.79
Stroke inpatient stay
Non-elective stay (10 days) 4171 NHS Reference Costs 2013–1476
Excess bed-day 275
TIA/mimic inpatient stay
Non-elective stay (4 days) 1775 NHS Reference Costs 2013–1476
Excess bed-day 235
Readmission 2837 NHS Reference Costs 2013–1476
Long-term carea
Stroke care after discharge for an independent patient
(annual cost)
1412 Sandercock et al., 200279
Stroke care after discharge for a dependent patient 18,578
a Stroke care after discharge includes ambulatory rehabilitation (use of therapists and residential facilities) and long-term
care (nursing home, carer/sheltered home and own home).
TABLE 3 Assumptions made for adjusting the cost of oxygen supplementation for patients when continuous
oxygen was prescribed for clinical reasons
No oxygen Nocturnal oxygen Continuous oxygen
Add 3 days of continuous oxygen Add 1.5 days of continuous oxygen Double the cost for the amount
of oxygen given
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Analysis
The EQ-5D-3L and mRS data were not available for all randomised patients, and therefore, multiple
imputation (MI) was used. MI is a statistical technique that retains overall population variability and the
relationship between observations, and is considered useful when > 10% of data are missing. As > 10%
of the data were missing within the trial, these were treated as missing at random and estimated using the
Markov chain Monte Carlo MI method. Imputation of missing EQ-5D-3L scores used methods proposed by
Simons et al.,80 in which the whole index score was imputed. The percentage of missing EQ-5D-3L data at
12 months was 18%; therefore, 25 simulated, complete versions of the data set were produced using
Stata 12.1 software (StataCorp LP, College Station, TX, USA). The results of each of the simulated data
sets were combined to produce estimates and CIs to incorporate missing data uncertainty. MI was carried
out at all time points. Appendix 4 contains further detail on the imputation methods.
As the majority of cost and outcome data are usually skewed, normal parametric methods are not
appropriate for calculation of the differences in means. Bootstrapping is a non-parametric approach that
can be used to compare arithmetic means without making any assumptions regarding the sampling
distribution. In this analysis, 3000 bootstrapping replications were undertaken in order to calculate the
95% CIs around the differences in mean costs and outcomes.
TABLE 4 Costs of oxygen supplementation
Resource use and cost per patient (UK £, 2013/14) Value (£) Source
Nocturnal ROS
Nursea 23.6 SO2S trial data (Curtis, 2014
77)
Allied professionalsb 23.0 SO2S trial data (Curtis, 2014
77)
Doctorc 1.9 SO2S trial data (Curtis, 2014
77)
Physiotherapist 1.5 SO2S trial data (Curtis, 2014
77)
Housekeeping 0.1 SO2S trial data (Curtis, 2014
77)
Oxygen tubing 4.4 SO2S trial data
Portable oxygen cylinder 2.7 SO2S trial data
Nasal tubes 6.5 SO2S trial data
Oxygen mask 0.6 SO2S trial data
Total cost per patient 64.0
Continuous ROS
Nursea 32.1 SO2S trial data (Curtis, 2014
77)
Allied professionalsb 29.0 SO2S trial data (Curtis, 2014
77)
Doctorc 1.8 SO2S trial data (Curtis, 2014
77)
Physiotherapist 2.2 SO2S trial data (Curtis, 2014
77)
Housekeeping 0.1 SO2S trial data (Curtis, 2014
77)
Oxygen tubing 4.4 SO2S trial data
Portable oxygen cylinder 5.6 SO2S trial data
Nasal tubes 6.7 SO2S trial data
Oxygen mask 0.6 SO2S trial data
Total cost per patient 83.0
a Including sister/charge nurse, staff/registered nurse, nurse, registered nurse and student/research nurse.
b Including health care assistant or trainee allied professional.
c Including consultant/stroke physician and specialist registrar.
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The incremental cost-effectiveness analysis was carried out at 12 months, based on the outcome of home
time gained, and the incremental cost-effectiveness ratio (ICER) was expressed in terms of the cost per
1 additional day of home time gained at 12 months. A CUA was also carried out at 12 months and the
ICERs were expressed as cost per additional QALY gained. The presentation of results in QALYs allows
comparison of the results with other available published studies. The analysis was conducted according
to the intention-to-treat principle, in line with the main trial analysis, and discounting was not applied
as the duration of follow-up was only 1 year. First, an analysis of ROS compared with no ROS was
conducted by including all patients in the nocturnal and continuous ROS arms in the overall ROS
comparator. A subsequent analysis considered all three trial arms, using the principle of dominance:
that is, if one of the trial arms was shown to be both more costly and less effective than at least one of
the alternative interventions, then that option would be seen as dominated and excluded from remainder
of the analysis.
A range of one-way deterministic sensitivity analyses were carried out to explore the robustness of the
base-case cost–utility results for ROS compared with no ROS, and to assess the uncertainty associated with
input parameters. The following sensitivity analyses were undertaken:
l changing the costs of oxygen treatment (increasing/reducing the costs by 20%)
l changing the acute inpatient costs of stroke (reducing/increasing the costs by 20%)
l changing the costs of stroke care after discharge (reducing/increasing the costs by 20%)
l assuming that quality of life changes between base-case and 3 months took place immediately,
therefore allocating the 3 month EQ-5D-3L value to baseline.
In addition, a probabilistic sensitivity analysis of the base-case analysis (cost-effectiveness analysis and CUA)
was carried out to enable the simultaneous exploration of uncertainty in the cost and outcome data, using
5000 simulations. The results of the probabilistic sensitivity analysis are presented using cost-effectiveness
planes and cost-effectiveness acceptability curves (CEACs). The CEAC graphically represents the probability
that an intervention is cost-effective at different ICER thresholds.
All analyses were carried out using Stata version 12.1 and Microsoft Excel® 2007 (Microsoft Corporation,
Redmond, WA, USA).
Patient and public involvement
We conducted focus group meetings with stroke survivors when preparing the protocol for SO2S
(see Ali et al.46 for detail). Stroke survivors and their carers considered the study important. They considered
the outcomes relevant, but suggested others that were not adequately covered by the formal assessment
tools. These included memory, speech problems and sleep. We designed questions to specifically address
these points and included them in the assessments at 3, 6 and 12 months. We also discussed consent
issues, as many stroke patients are unable to give fully informed consent soon after the stroke, because
of the nature of their brain injury. Some of the stroke patients were concerned that asking relatives to
provide consent on behalf of the patients would put them under too much stress at a time when they
were anxious and worried. We explained that there was an option of allowing an independent physician
to consent on behalf of the patient. We included patient and carer representatives as collaborators and as
members of the trial management group. Over the time of the study the initial collaborators (Linda and
Peter Handy) became unable to contribute further for health reasons. Towards the end of the study
Norman Phillips and Brin Helliwell provided advice to the trial management group and input into
the report.
DOI: 10.3310/hta22140 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 14
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Roffe et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Ethical approval
The protocol was approved by the North Staffordshire Ethics Committee (06/2604/109) on 24 January 2007.
The protocol can be accessed at http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-99
(accessed 1 June 2016).
Clinical trials registration
European Union Drug Regulating Authorities Clinical Trials (EudraCT) number 2006-003479-11 and
Current Controlled Trials International Standard Randomised Controlled Trial Number (ISRCTN) 52416964.
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Chapter 3 Results
Recruitment
In total 8003 patients were recruited between 24 April 2008 and 17 June 2013 (Figure 2). Participants 
were randomised to the three groups: 2668 to the control group, 2668 to the continuous oxygen group 
and 2667 to the nocturnal oxygen group. All follow-up assessments were completed by December 2014.
Consent and patient flow through the study
Fully informed consent was given by 6991 (87%) of patients and assent was given by a relative, carer or 
independent legal representative for 1012 (13%) patients (Table 5). At the 7-day review, six (0.7%) 
assented patients refused consent and were withdrawn from the study. A further 22 assented patients 
were withdrawn between days 7 and 90, six between days 90 and 180, and two between day 180 and 
the end of the study. Of those patients who gave informed consent, 40 were withdrawn by day 7, 114 
were withdrawn from the study between day 7 and day 90 post randomisation, 37 were withdrawn 
between day 90 and 180, and 30 withdrew between days 180 and 365 (Figure 3).
Baseline data
Patient age and sex distribution were similar in all three groups. Overall mean age was 72 years (SD 13 years) 
and in total 4398 (55%) patients were male. Prognostic factors, including independence in activities of daily 
living before the stroke (n = 7332, 92%), were also well matched across the trial arms. There was little to no 
difference in the participants’ medical history, with ischaemic heart disease (n = 1602, 20%), heart failure
(n = 657, 8%), atrial fibrillation (n = 1995, 25%) and chronic lung conditions (n = 812, 10%) recorded in 
each group. Patients were enrolled relatively late at a median 20:43 (IQR 11:59–25:32) hours:minutes after 
symptom onset. The majority of patients had a final diagnosis of ischaemic stroke (n = 6555, 82%) recorded 
at the 7-day review. Primary intracerebral haemorrhage was diagnosed in 588 (7%) patients, TIA in 168
(2%) and non-stroke conditions in 292 (4%); this information was missing for 106 patients (1%). The 
median GCS score was 15 (IQR 15–15) and mean and median NIHSS scores were 7 and 5, respectively
(range 0–34); again these were well balanced across the trial arms. Twenty per cent of patients received 
oxygen prior to randomisation and the mean oxygen saturation was 96.6% in the continuous (SD 1.7) and 
nocturnal oxygen (SD 1.6) treatment groups, and 96.7% (SD 1.7) in the control group (Table 6).
Treatment adherence
Treatment adherence in the two intervention arms was similar, with 2158 (81%) patients completing
the 72 hours of continuous oxygen therapy and 2225 (83%) patients receiving the nocturnal oxygen.
In the continuous group, 433 (16%) patients did not receive the full 72 hours of oxygen therapy, and
in the nocturnal group 361 (14%) did not. Discharge from hospital was the main reason for stopping 
before the 72 hours had passed (Table 7). In the control group trial oxygen was not prescribed for
2229 (84%) participants, but was prescribed for 23 (1%) participants; this information was not available 
for 406 (15%) control participants.
In a subgroup of 4144 patients spot checks of adherence to oxygen treatment were made at 00:00
and 06:00 on nights 1, 2, and 3 of the intervention (Table 8). On the first night, adherence to oxygen 
treatment was reasonable, with oxygen in place for 82% and 78% for the continuous and nocturnal 
oxygen groups, respectively, at midnight and in 82% and 72%, respectively, at 06:00. During nights 2 and 
3, considerably fewer spot checks were recorded as positive, with the lowest being 56% and 51% for the 
continuous and nocturnal oxygen groups at 06:00 of night 3. In the control group, oxygen
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TABLE 5 Cumulative withdrawal data for SO2S study at each of the follow-up time points
Variable
Trial arm
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Consent given by the patient, n (%) 2329 (87) 2340 (88) 2322 (87)
Consent given by a relative, carer or independent legal
representative, n (%)
339 (13) 327 (12) 346 (13)
Withdrawal from trial by 7 days, n (%)
Total 16 (0.6) 20 (0.7) 4 (0.15)
Patients who gave initial consent themselves 14 (0.5) 17 (0.6) 3 (0.11)
Patients included by a legal representative 2 (0.1) 3 (0.1) 1 (0.04)
Withdrawal from trial by 90 days, n (%)
Total 56 (2.1) 63 (2.4) 57 (2.1)
Patients who gave initial consent themselves 48 (1.8) 56 (2.1) 44 (1.6)
Patients included by a legal representative 8 (0.3) 7 (0.3) 13 (0.5)
Withdrawal from trial by 180 days, n (%)
Total 77 (2.9) 72 (2.7) 70 (2.6)
Patients who gave initial consent themselves 67 (2.5) 63 (2.4) 55 (2.1)
Patients included by a legal representative 10 (0.4) 9 (0.3) 15 (0.6)
Withdrawal from trial by 365 days, n (%)
Total 89 (3.3) 81 (3.0) 81 (3.0)
Patients who gave initial consent themselves 78 (2.9) 71 (2.7) 66 (2.5)
Patients included by a legal representative 11 (0.4) 10 (0.4) 15 (0.6)
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FIGURE 2 Timeline of patients recruited to SO2S over a 5-year period.
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Enrolled 
(n = 8003)
Randomised 
(n = 8003)
Assigned continuous oxygen 
(n = 2668)
Assigned control
(n = 2668)
Assigned nocturnal oxygen 
(n = 2667)
• Lost to follow-up, n = 1
• Withdrawn, n = 16
   • Withdrawn consent, n = 9
   • Patient did not like 
      treatment, n = 5
   • Did not state reason, n = 1
   • Other, n = 1
• Lost to follow-up, n = 35
• Withdrawn, n = 40
   • Withdrawn consent, n = 25
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 5
   • Not a stroke, n = 3
   • Patient not well, n = 4
   • Other, n = 3
• Lost to follow-up, n = 0
• Withdrawn, n = 21
   • Withdrawn consent, n = 9
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 3
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 9
• Lost to follow-up, n = 0
• Withdrawn, n = 12
   • Withdrawn consent, n = 7
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 2
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 3
Assessed at 7 days 
(n = 2651)
Assessed at 90 days 
(n = 2576)
Assessed at 180 days 
(n = 2555)
Assessed at 365 days 
(n = 2543)
• Lost to follow-up, n = 1
• Withdrawn, n = 20
   • Withdrawn consent, n = 8
   • Patient did not like 
      treatment, n = 4
   • Did not state reason, n = 1
   • Other, n = 7
• Lost to follow-up, n = 27
• Withdrawn, n = 43
   • Withdrawn consent, n = 26
   • Patient did not like 
      treatment, n = 1
   • Patient left country, n = 1
   • Did not state reason, n = 5
   • Not a stroke, n = 2
   • Patient not well, n = 5
   • Other, n = 3
• Lost to follow-up, n = 0
• Withdrawn, n = 9
   • Withdrawn consent, n = 6
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 1
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 2
• Lost to follow-up, n = 1
• Withdrawn, n = 9
   • Withdrawn consent, n = 4
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 3
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 2
Assessed at 7 days 
(n = 2646)
Assessed at 90 days 
(n = 2576)
Assessed at 180 days 
(n = 2567)
Assessed at 365 days 
(n = 2557)
• Lost to follow-up, n = 0
• Withdrawn, n = 4
   • Withdrawn consent, n = 2
   • Patient did not like 
      treatment, n = 0
   • Did not state reason, n = 1
   • Other, n = 1
• Lost to follow-up, n = 44
• Withdrawn, n = 53
   • Withdrawn consent, n = 23
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 0
   • Did not state reason, n = 8
   • Not a stroke, n = 5
   • Patient not well, n = 3
   • Other, n = 14
• Lost to follow-up, n = 0
• Withdrawn, n = 13
   • Withdrawn consent, n = 7
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 1
   • Did not state reason, n = 2
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 3
• Lost to follow-up, n = 2
• Withdrawn, n = 11
   • Withdrawn consent, n = 6
   • Patient did not like 
      treatment, n = 0
   • Patient left country, n = 1
   • Did not state reason, n = 2
   • Not a stroke, n = 0
   • Patient not well, n = 0
   • Other, n = 2
Assessed at 7 days 
(n = 2664)
Assessed at 90 days 
(n = 2567)
Assessed at 180 days 
(n = 2554)
Assessed at 365 days 
(n = 2541)
FIGURE 3 Consolidated Standards of Reporting Trials (CONSORT) flow chart for SO2S.
DOI: 10.3310/hta22140 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 14
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Roffe et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
TABLE 6 Baseline characteristics of patients recruited to SO2S
Variable
Trial arm
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Demographic characteristics
Age (years)
Mean (SD)a 72 (13) 72 (13) 72 (13)
Median (IQR) 74 (64–82) 75 (65–82) 74 (64–82)
Male sex; n (%)a 1466 (55) 1466 (55) 1466 (55)
Prognostic factors
Living alone, n (%)a 861 (32) 857 (32) 907 (34)
Independent in basic activities of daily living,
n (%)a
2451 (92) 2431 (91) 2450 (92)
Normal verbal response, n (%)a 2190 (82) 2207 (83) 2196 (82)
Able to lift affected arm, n (%)a 1998 (75) 2022 (76) 1996 (75)
Able to walk, n (%)a 660 (25) 704 (26) 677 (25)
Probability of 30-day survival, median (IQR) 0.92 (0.86–0.95) 0.92 (0.86–0.95) 0.92 (0.86–0.95)
Probability of being alive and independent at
6 months, median (IQR)a
0.44 (0.12–0.71) 0.42 (0.12–0.71) 0.42 (0.12–0.71)
Blood glucose (mmol/l), mean (SD) 7.1 (2.5) 7.0 (2.4) 7.1 (2.5)
Concomitant medical problems
Ischaemic heart disease, n (%) 573 (21) 515 (19) 514 (19)
Heart failure, n (%) 224 (8) 217 (8) 216 (8)
Atrial fibrillation, n (%) 638 (24) 673 (25) 684 (26)
Chronic obstructive pulmonary disease/asthma,
n (%)
253 (9) 242 (9) 245 (9)
Other chronic lung problem, n (%) 29 (1) 24 (1) 19 (1)
Details of the qualifying event
Time since symptom onset (hh:mm), mean (IQR)b 20:44 (11:53–25:33) 20:32 (12:05–25:31) 20:45 (11:57–25:31)
Ischaemic stroke, n (%)b 2187 (82.0) 2165 (81.1) 2203 (82.6)
Intracranial haemorrhage, n (%)b 185 (6.9) 207 (7.8) 196 (7.3)
TIA, n (%)b 52 (1.9) 50 (1.9) 66 (2.5)
Stroke without imaging diagnosis, n (%)b 104 (3.9) 106 (4.0) 84 (3.1)
Not a stroke, n (%)b 101 (3.8) 98 (3.7) 93 (3.5)
Missing, n (%)b 39 (1.5) 41 (1.5) 26 (1.0)
GCS score (3–15), median (IQR) 15 (15–15) 15 (15–15) 15 (15–15)
Thrombolysed, n (%)b 447 (17) 410 (15) 447 (17)
NIHSS score (0–42), median (IQR) 5 (3–9) 5 (3–9) 5 (3–9)
Oxygenation
Oxygen given prior to randomisation (yes), n (%)a 531 (20) 531 (20) 539 (20)
Oxygen saturation on room air (%), mean (SD)a 96.6 (1.7) 96.6 (1.6) 96.7 (1.7)
a Minimisation variables.
b Data were recorded on day 7.
Data in this table were collected before randomisation unless marked as otherwise.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
was recorded as being in place at 00:00 in 2%, 3%, and 3% at 00:00 on nights 1, 2, and 3, respectively,
and in 3% at 06:00 for each of the 3 days. The percentages are for a total of all patients randomised after
the protocol change and included patients who were no longer in hospital.
Primary outcome
The distribution of scores for mRS at 90 days is shown in Figure 4. Oxygen supplementation did not
improve the level of disability either in the comparison of the combined oxygen group against control or
in the comparison of continuous versus nocturnal oxygen, both in the primary unadjusted analysis and in
the covariate-adjusted analysis. The unadjusted OR for a better outcome (lower mRS) was 0.97 (95% CI
0.89 to 1.05; p = 0.5) for combined oxygen versus control (see Figure 4a), and 1.03 (95% CI 0.93 to 1.13;
p = 0.6) for continuous oxygen versus nocturnal oxygen (see Figure 4b). Analyses adjusted for the
covariates age, sex, baseline NIHSS score, baseline oxygen saturation and the SSV prognostic index yielded
very similar results [an OR of 0.97 (95% CI 0.89 to 1.06; p = 0.5) for the combined oxygen group vs.
control and an OR of 1.01 (95% CI 0.92 to 1.12; p = 0.8) for continuous oxygen vs. oxygen at night only].
The primary outcome of the SO2S was the mRS score at 90 days post stroke as a measure of disability
and dependence: (1) comparing the control group (no oxygen supplementation) with both the continuous
(72 hours, day and night) and nocturnal (for three nights only) groups combined; and (2) comparing
continuous oxygen with nocturnal oxygen.
Sensitivity analyses for the primary outcome
Sensitivity analyses (Table 9) show very similar results for the complete case analysis and the analysis using
MI for missing values, both confirming that oxygen treatment does not improve the primary outcome.
The best- and worst-case imputations indicate the plausible maximum bounds of any potential bias from
TABLE 7 Adherence to trial treatment
Variable
Trial arm
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Trial oxygen prescribed in the drug chart and signed, n (%) 1369 (51.3) 1426 (53.5) 21 (0.8)
Trial oxygen prescribed in the drug chart but not signed, n (%) 789 (29.6) 799 (30) 2 (0.1)
Trial oxygen stopped before 72 hours, n (%) 433 (16.2) 361 (13.5) 10 (0.4)
No oxygen prescribed for the trial as per randomisation, n (%) 4 (0.2) 10 (0.4) 2229 (83.5)
No data, n (%) 73 (2.7) 71 (2.6) 406 (15.2)
TABLE 8 Spot checks of adherence to the trial intervention in a subgroup of 4144 patients
Variable
Trial arm
Continuous oxygen
(N= 1381)
Nocturnal oxygen
(N= 1381)
Control
(N= 1382)
Staff checked and signed that oxygen is in place at midnight
Night 1, n (%) 1134 (82) 1074 (78) 31 (2)
Night 2, n (%) 970 (70) 931 (67) 38 (3)
Night 3, n (%) 803 (58) 772 (56) 37 (3)
Staff checked and signed that oxygen is in place at 6 am
Night 1, n (%) 1132 (82) 994 (72) 37 (3)
Night 2, n (%) 954 (69) 863 (62) 45 (3)
Night 3, n (%) 774 (56) 703 (51) 39 (3)
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FIGURE 4 The primary outcome: mRS at 3 months. (a) Comparison 1 (combined oxygen vs. control); and
(b) comparison 2 (continuous oxygen vs. nocturnal oxygen). Adapted with permission from Roffe et al.81
TABLE 9 Sensitivity analyses
Variable
OR (95% CI); p-value
Oxygen vs. no oxygena Continuous vs. nocturnalb
Complete case analysis 0.970 (0.892 to 1.054); 0.471 1.025 (0.931 to 1.129); 0.611
MI analysisc 0.974 (0.895 to 1.061); 0.549 1.031 (0.933 to 1.135); 0.530
Best-case imputationd 1.178 (1.085 to 1.279); < 0.001 1.221 (1.111 to 1.342); < 0.001
Worst-case imputatione 0.803 (0.740 to 0.872); < 0.001 0.862 (0.784 to 0.947); 0.002
Adherers onlyf 0.925 (0.833 to 1.028); 0.148 0.981 (0.853 to 1.127); 0.782
Analyses are unadjusted unless specified otherwise.
a Reference category is ‘no oxygen’; outcome is a 1-point lower (better) score on mRS.
b Reference category is ‘nocturnal’; outcome is a 1-point lower (better) score on mRS.
c Based on 20 imputed data sets.
d Missing values for ‘oxygen’ and ‘continuous’ are given a good score (0 or 1), missing cases for ‘no oxygen’ and
‘nocturnal’ are given a poor score (5 or 6); CIs and p-values have been adjusted for the imputation.
e Missing values for ‘oxygen’ and ‘continuous’ are given a poor score (5 or 6), missing cases for ‘no oxygen’ and
‘nocturnal’ are given a good score (0 or 1); CIs and p-values have been adjusted for the imputation.
f Trial oxygen prescribed and signed as given: control, n= 1994; continuous Oxygen, n= 1285; nocturnal Oxygen,
n= 1250; combined Oxygen, n = 2535. Analysis adjusted for age, sex, baseline NIHSS score, baseline oxygen saturation,
and SSV prognostic index for 6-month independence, to account for loss of equivalence from randomisation.
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missing data (under a missing not at random assumption), showing improvement in outcome for oxygen
for the best-case analysis and worse outcomes with oxygen for the worst-case analysis, with similar effect
sizes in both directions. The adherers-only analyses showed a minor difference between the combined
oxygen groups and control, with slightly lower odds for a good outcome with oxygen for the comparison
of the combined oxygen groups with control, which was not statistically significant.
Subgroup analyses
The predefined subgroup analyses are shown in Figure 5. There was no indication that treatment
effectiveness differed for any of the predefined subgroups (oxygen treatment before enrolment, oxygen
Oxygen concentration at randomisation
< 94%
94–94.9%
95–97%
> 97%
NIHSS score at baseline
0–4
5–9
10–14
15–20
> 20
Final diagnosis
Ischaemic stroke
TIA
Primary intracerebral haemorrhage
Cerebrovascular accident without CT
or confirmation of aetiology
Other
Time since stroke onset
< 4 hours
4–6 hours
7–12 hours
13–24 hours
> 24 hours
Aetiology of cerebral infarcts (TOAST)
Large-artery atherosclerosis
Cardioembolism
Small-artery occlusion (lacunar infarct)
Acute ischaemic stroke of other 
determined aetiology
Ischaemic stroke of undetermined
aetiology
Age at randomisation
< 50 years
50–80 years
> 80 years
SSV risk score
SSV < 0.1
SSV 0.1–0.35
SSV 0.36–0.7
SSV > 0.7
COPD status
No COPD
COPD
Heart failure
No CCF
CCF
Level of consciousness
GCS eye and motor score < 10
GCS eye and motor score = 10
Oxygen before randomisation
No oxygen
Oxygen
Thrombolysis performed
No thrombolysis
Thrombolysis
All patients
Oxygen (n/N)
Intervention
53/145
164/333
1588/3074
836/1576
1595/2269
800/1619
183/636
50/354
13/250
2183/4222
68/99
159/381
117/205
104/178
92/175
262/499
355/710
1069/2045
856/1687
275/651
446/938
487/773
114/221
911/1698
216/310
1880/3291
545/1527
238/1185
439/1079
994/1578
970/1286
2397/4649
244/479
2490/4703
151/425
111/565
2530/4563
2190/4031
426/1030
2168/4265
467/832
2641/5128
37/95
75/144
785/1482
440/828
838/1172
387/755
79/302
25/212
8/108
1109/2112
44/63
79/192
49/80
51/81
50/92
123/240
180/354
542/1017
440/839
150/348
238/485
238/374
53/101
445/822
118/164
927/1599
292/786
119/593
242/539
485/786
491/631
1206/2313
131/236
1253/2345
84/204
63/288
1274/2261
1082/2000
237/516
1097/2107
239/432
1337/2549
No oxygen (n/N) Odds ratio (99% CI)
0.90 (0.45 to 1.82)
0.89 (0.53 to 1.49)
0.95 (0.81 to 1.12)
1.00 (0.80 to 1.24)
0.94 (0.77 to 1.16)
0.93 (0.74 to 1.17)
1.14 (0.76 to 1.71)
1.23 (0.63 to 2.42)
0.69 (0.21 to 2.27)
0.97 (0.84 to 1.11)
0.95 (0.38 to 2.33)
1.02 (0.64 to 1.63)
0.84 (0.42 to 1.68)
0.83 (0.41 to 1.68)
0.93 (0.48 to 1.81)
1.05 (0.70 to 1.58)
0.97 (0.69 to 1.35)
0.96 (0.79 to 1.17)
0.93 (0.75 to 1.16)
0.97 (0.68 to 1.36)
0.94 (0.71 to 1.25)
0.97 (0.69 to 1.36)
0.96 (0.52 to 1.79)
0.98 (0.79 to 1.22)
0.90 (0.52 to 1.55)
0.97 (0.82 to 1.13)
0.94 (0.74 to 1.19)
1.00 (0.72 to 1.38)
0.84 (0.64 to 1.11)
1.06 (0.84 to 1.33)
0.88 (0.65 to 1.18)
0.98 (0.86 to 1.11)
0.83 (0.55 to 1.26)
0.98 (0.86 to 1.12)
0.79 (0.50 to 1.23)
0.87 (0.55 to 1.38)
0.96 (0.84 to 1.10)
1.01 (0.88 to 1.16)
0.83 (0.63 to 1.10)
0.95 (0.83 to 1.09)
1.03 (0.76 to 1.41)
0.96 (0.85 to 1.09)
0.94
0.59
0.95
0.98
1.00
0.92
0.34
0.34
0.23
0.59
0.11
0.53
0.43
p-value
0.25 0.50 0.75 1.00 1.50
Favours oxygenFavours no oxygen
2.00 2.50
FIGURE 5 Forest plot of subgroup analyses: alive and independent (mRS score of ≤ 2) at 3 months of oxygen
(continuous and nocturnal combined) compared with control. n is the total number of events and N is the total number
of events plus non-events for that group. COPD, chronic obstructive pulmonary disease; CCF, congestive cardiac failure.
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saturation on air at randomisation, NIHSS score, final diagnosis, time since stroke onset, aetiology, age, SSV
prognostic index, level of consciousness, and history of heart failure or of chronic obstructive airways disease).
Secondary and explanatory outcomes at 1 week
Oxygenation
Results for the highest oxygen saturation, the lowest oxygen saturation, the number of patients who had
desaturations below 90% and the number of patients who needed additional oxygen over and above
the trial prescription during the first 72 hours are shown in Table 10. The highest and lowest oxygen
saturations recorded during the treatment period increased significantly (p < 0.001), by 0.8% and 0.9%
respectively, in the continuous oxygen group when compared with the control group. This was also seen
in the nocturnal oxygen group with highest and lowest oxygen saturations increased by 0.5% and 0.4%,
respectively (p < 0.001). Severe hypoxia was recorded in a small number of patients (143, 2%), but was
significantly less common in the combined oxygen group than in the control group. Significantly more
patients in the combined oxygen group than in the control group required oxygen in addition to the trial
intervention (OR 1.36, 99% CI 1.07 to 1.73; p = 0.0008). This was also not statistically different when
comparing continuous with nocturnal oxygen (OR 1.23, 99% CI 0.96 to 1.59; p = 0.03), as significance
was defined as < 0.01 for secondary outcomes.
Neurological recovery at 1 week
Data for neurological recovery and mortality at 1 week are shown in Table 11. The median (IQR) NIHSS
score at week 1 was 2 (1–6) in all three treatment groups. There was no difference in the number of
patients who improved by 4 or more NIHSS points between baseline and week 1. Mortality by day 7 was
very low in all three treatment groups with 50 (1.9%), 35 (1.3%) and 45 (1.7%) deaths in the continuous
oxygen, nocturnal oxygen and control groups, respectively.
Explanatory analysis at 1 week
Exploratory analyses (see Table 11) did not show evidence of increased stress levels (higher heart rates,
higher blood pressure, or need for sedation) in oxygen-treated patients compared with control patients.
There was also no evidence that oxygen treatment was associated with more infections, with no
differences in the highest temperature or the need for antibiotics.
Secondary and exploratory outcomes at 3 months
There was no difference in mortality, the number of patients alive and independent at 3 months,
the number of participants who lived at home, the BI, the NEADL, EQ-5D-3L, EQ-VAS, sleep, speech or
memory between the oxygen-treated and control groups or between the groups receiving continuous and
nocturnal oxygen treatment (Table 12).
Long-term outcomes (3, 6 and 12 months)
Survival
Mortality at 90 days (Figure 6) was similar in the oxygen (both groups combined) and control groups
(hazard ratio 0.97, 99% CI 0.78 to 1.21; p = 0.8) and in the groups recieving continuous oxygen or
oxygen at night only (hazard ratio 1.15, 99% CI 0.90–1.48; p = 0.1).
Survival was the same throughout the 365 days of follow-up for patients treated with continuous oxygen
and with nocturnal oxygen, and those in the control group (Figure 7).
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TABLE 10 Oxygenation-related secondary outcomes
Variable n (N= 8003)
Trial arm
Oxygen vs.
control, OR or
MD (99% CI)
Oxygen vs. control,
p-value
Continuous vs.
nocturnal, OR or
MD (99% CI)
Continuous
vs. nocturnal,
p-value
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Highest oxygen
saturation (%)a
7860 99.1 (99.1 to 99.2),
n= 2620
98.8 (98.7 to 98.9),
n= 2609
98. 3 (98.2 to 98.3),
n= 2631
0.69 (0.61 to 0.77) < 0.0001c 0.32 (0.22 to 0.41) < 0.0001c
Lowest oxygen
saturation (%)a
7860 95.0 (94.9 to 95.1),
n= 2619
94.5 (94.4 to 94.6),
n= 2610
94.1 (94.0 to 94.2),
n= 2631
0.62 (0.48 to 0.76) < 0.0001c 0.48 (0.32 to 0.63) < 0.0001c
Oxygen saturation
< 90%b
7860 39 (1.5%), n= 2619 30 (1.1%), n= 2610 74 (2.8%), n = 2631 0.46 (0.30 to 0.71) < 0.0001d 1.30 (0.69 to 2.44) 0.27d
Need for additional
oxygenb
7809 254 (9.8%), n= 2599 209 (8.1%), n= 2589 176 (6.7%), n = 2621 1.36 (1.07 to 1.73) 0.0008d 1.23 (0.96 to 1.59) 0.03d
MD, mean difference.
a Data are given as means and 95% CIs.
b Data are given as numbers and percentages.
c Significance testing was by unrelated t-test.
d Significance testing was by chi-squared test.
MDs are reported for means, and ORs for frequencies.
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TABLE 11 Secondary and exploratory outcomes at 1 week
Variable n (N= 8003)
Trial arm
Oxygen vs. control,
OR or MD (99% CI)
Oxygen vs. control,
p-value
Continuous vs.
nocturnal, OR or
MD (99% CI)
Continuous
vs. nocturnal,
p-value
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Neurological
improvement, n (%)
7778 1016 (39.2%),
n= 2591
1029 (39.7%),
n = 2591
1037 (39.9%),
n = 2596
0.98 (0.86 to 1.11) 0.68a 0.98 (0.85 to 1.13) 0.71a
NIHSS, median (IQR) 7778 2 (1–6),
n= 2591
2 (1–6),
n = 2591
2 (1–6),
n = 2596
–0.04 (–0.43 to 0.34) 0.78b 0.12 (–0.32 to 0.57) 0.47b
Death by 7 days,
n (%)
7959 50 (1.9%),
n= 2651
35 (1.3%),
n = 2645
45 (1.7%),
n = 2663
0.95 (0.59 to 1.53) 0.78a 1.43 (0.81 to 2.54) 0.11a
Highest heart rate
(b.p.m.), mean (SD)
7859 87.2 (16.6),
n= 2618
88.0 (16.5),
n = 2609
87.7 (15.7),
n = 2632
–0.07 (–1.06 to 0.92) n/a –0.83 (–2.01 to 0.35) n/a
Highest systolic
blood pressure
(mmHg), mean (SD)
7864 162.4 (24.6),
n= 2621
162.8 (24.8),
n = 2610
164.6 (24.7),
n = 2633
–1.96 (–3.48 to 0.44) n/a –0.35 (–2.11 to 1.41) n/a
Highest diastolic
blood pressure
(mmHg), mean (SD)
7861 89.5 (15.3),
n= 2621
90.2 (15.5),
n = 2609
90.9 (15.7),
n = 2631
–1.10 (–2.06 to 0.15) n/a –0.72 (–1.82 to 0.37) n/a
Highest systolic
blood pressure
> 200mmHg (n)
7864 180,
n= 2621
186,
n = 2610
205,
n = 2633
n/a n/a n/a n/a
Highest diastolic
blood pressure
> 100mmHg (n)
7861 531,
n= 2621
552,
n = 2609
606,
n = 2631
n/a n/a n/a n/a
Sedative use, n (%) 7916 140 (5.3%),
n= 2634
161 (6.1%),
n = 2631
154 (5.8%),
n = 2651
0.98 (0.76 to 1.28) n/a 0.86 (0.63 to 1.17) n/a
Antibiotic
treatment, n (%)
7916 400 (15.2%),
n= 2634
393 (14.9%),
n = 2631
403 (15.2%),
n = 2651
0.99 (0.83 to 1.17) n/a 1.02 (0.84 to 1.24) n/a
Highest temperature
(°C) up to 7 days,
mean (SD)
7877 37.1 (0.6),
n= 2623
37.2 (0.6),
n = 2617
37.1 (0.6),
n = 2637
0.01 (–0.03 to 0.04) n/a –0.01 (–0.05 to 0.03) n/a
b.p.m., beats per minute; MD, mean difference; n/a, not applicable.
a Significance testing was by chi-squared test.
b Significance testing was by unrelated t-test.
Secondary outcomes were neurological improvement, and mortality 7 days post randomisation. Blood pressure and heart rate during the first 72 hours and temperature, sedative use, and
antibiotic treatment up to day 7 were exploratory outcomes. Exploratory outcomes were not analysed statistically. Neurological improvement was defined as a ≥ 4-point decrease from
baseline or a value of 0 for NIHSS at 7 days.
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
26
TABLE 12 Secondary and exploratory outcomes at 3 months
Variable n (N= 8003)
Trial arm
Oxygen vs. control,
OR or MD (99% CI)
Oxygen vs. control,
p-value
Continuous vs.
nocturnal, OR or MD
(99% CI)
Continuous
vs. nocturnal,
p-value
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Death by 3 months 7677 257 (10.0%),
n = 2567
236 (9.2%),
n= 2561
246 (9.7%),
n= 2549
1.00 (0.81 to 1.23) 0.96b 1.10 (0.86 to 1.40) 0.33b
Death by 90 daysa
(date)
8003 222 (8.3%),
n = 2668
194 (7.3%),
n= 2667
214 (8.0%),
n= 2668
0.97 (0.77 to 1.22) 0.73b 1.16 (0.89 to 1.51) 0.15b
Alive and
independenta
7677 1325 (51.6%),
n = 2567
1316 (51.4%),
n= 2561
1337 (52.5%),
n= 2549
0.96 (0.85 to 1.09) 0.43b 1.01 (0.87 to 1.17) 0.87b
Living at homea 6859 1961 (85.8%),
n = 2285
1947 (84.8%),
n= 2295
1947 (85.4%),
n= 2279
0.99 (0.82 to 1.20) 0.91b 1.08 (0.87 to 1.34) 0.35b
Barthel ADL index
[0 (worst) to 100
(best)]c
6549 70.2 (68.7 to 71.8),
n = 2169
71.1 (69.6 to 72.6),
n= 2194
70.9 (69.3 to 72.4),
n= 2186
–0.18 (–2.60 to 2.24) 0.85d –0.86 (–3.65 to 1.93) 0.43d
Nottingham
Extended ADL
[0 (worst) to
21 (best)]c
7528 9.66 (9.38 to 9.93),
n = 2520
9.54 (9.26 to 9.81),
n= 2501
9.77 (9.49 to 10.05),
n= 2507
–0.17 (–0.62 to 0.28) 0.32d 0.12 (–0.40 to 0.64) 0.55d
Quality of life
(EQ-5D-3L) [–0.59
(worst) to 1 (best)]c
7248 0.50 (0.48 to 0.51),
n = 2413
0.50 (0.48 to 0.51),
n= 2428
0.49 (0.48 to 0.51),
n= 2407
0.004 (0.02 to 0.03) 0.71d –0.003 (–0.03 to 0.03) 0.78d
Quality of life
(EQ-VAS) [0 (worst)
to 100 (best)]c
6675 55.4 (54.2 to 56.7),
n = 2251
55.7 (54.4 to 56.9),
n= 2216
55.5 (54.2 to 56.7),
n= 2208
0.10 (–1.93 to 2.12) 0.90d –0.24 (–2.57 to 2.09) 0.79d
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TABLE 12 Secondary and exploratory outcomes at 3 months (continued )
Variable n (N= 8003)
Trial arm
Oxygen vs. control,
OR or MD (99% CI)
Oxygen vs. control,
p-value
Continuous vs.
nocturnal, OR or MD
(99% CI)
Continuous
vs. nocturnal,
p-value
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Sleep as good as
before the strokea
6584 1407 (64%),
n = 2194
1436 (65%),
n= 2208
1419 (65%),
n= 2182
0.98 (0.85 to 1.13) – 0.96 (0.82 to 1.13) –
No significant
speech problemsa
6716 1957 (88%),
n = 2229
1957 (87%),
n= 2246
1939 (87%),
n= 2241
1.09 (0.89 to 1.32) – 1.06 (0.84 to 1.34) –
Memory as good as
before the strokea
6646 981 (44%),
n = 2222
1000 (45%),
n= 2224
971 (44%),
n= 2200
1.02 (0.89 to 1.16) – 0.97 (0.83 to 1.13) –
ADL, activities of daily living; EQ-5D-3L, European Quality of Life-5 DImensions, three levels; MD, mean difference.
a Data are given as numbers and percentages.
b Significance testing was by chi-squared test.
c Data are given as means and 99% CIs.
d Significance testing was by unrelated t-test.
MDs are reported for means, and ORs for numbers. Alive and independent is a mRS score of two or fewer. As outlined in the statistical analysis plan, we have not conducted significance
tests on the exploratory data and the outcomes suggested by patients and carers.
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FIGURE 6 Kaplan–Meier survival graph comparing (a) oxygen (combined) with control (no ROS) at 90 days; and (b) continuous vs. nocturnal oxygen. Oxygen compared with no
oxygen: unadjusted hazard ratio for a worse outcome – 0.97 (99% CI 0.78 to 1.21; p= 0.8). Continuous compared with nocturnal oxygen: unadjusted hazard ratio for a worse
outcome –1.15 (99% CI 0.90 to 1.48; p = 0.1).
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FIGURE 7 Kaplan–Meier survival graph comparing (a) oxygen (combined) with control (no ROS) at 365 days; and (b) continuous compared with nocturnal oxygen.
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Functional outcomes
Figure 8 shows the mean mRS score at 3, 6 and 12 months. There was no change in the level of disability
over the 3-, 6- and 12-month follow-up assessment points in any of the three groups. The proportion of
patients in each mRS score category is shown in Figure 9 for the combined oxygen group compared with
the control group and in Figure 10 for the continuous oxygen group compared with the nocturnal oxygen
group. Oxygen has no effect on the level of disability at any time point, whether given continuously or at
night only.
The number of patients who are alive and independent was similar in all three treatment groups and
did not change with time (52%, 53% and 53%, respectively, at each of the three time points).
Performance of activities of daily living (BI), ability to conduct extended activities of daily living (NEADL),
and quality of life (EQ-5D-3L) were no different between the combined oxygen groups or between
continuous and nocturnal oxygen at 90, 180 and at 365 days and were similar at each of the three time
points (Table 13).
Outcomes considered important by stroke survivors
Outcomes considered important by stroke survivors during the pre-study focus group meetings
(sleep, speech and memory) are shown in Table 13. There was also no difference in these outcomes
between the continuous oxygen, nocturnal oxygen and control groups. At 90 days, 87% had no
significant speech problems and 65% considered their sleep as good as before the stroke, but only
44% reported their memory as being as good as before the stroke. The data were similar at 180 and
365 days.
Length of hospital stay and readmissions
Data on length of stay were available for 2435 (91%), 2401 (90%) and 2446 (92%) of participants in
the continuous oxygen, nocturnal oxygen and control groups. The mean (SD) length of stay in hospital
was 18.6 days (50.9 days), 18.6 days (52.0 days) and 18.0 days (56.4 days), respectively (Table 14).
The rate of readmissions (Table 15) increased with time, but was similar for all three treatment groups
(14%, 17% and 20% at 3, 6 and 12 months, respectively).
Place of abode
Details of place of abode throughout the follow-up period are shown in Table 15. The proportion of
patients living in their own homes, with relatives, in residential nursing, or continuing care homes was
similar in all three groups. The proportion of participants living in their own homes or with family members
was 76%, 74% and 68% at 3, 6 and 12 months. Only a few patients were residing in institutions
(care home, nursing home or continuing NHS care) at each of the three time points (7%, 7% and 6%,
respectively).
Blinding
Details of who completed the follow-up questionnaires, and whether or not the person completing the
questionnaire remembers the treatment the participant was allocated to, are presented in Table 16. The
proportion of participants who completed the follow-up questionnaires personally and unaided by another
person was 33%, 29% and 28% at 3, 6 and 12 months. The proportions were similar for all three groups.
As participants were not blinded to the intervention, we included a question at follow-up to assess
whether or not they remembered which treatment group they were in. At 3 months, 49%, 35% and
45% in the continuous oxygen group, the nocturnal oxygen group and the control group, respectively,
remembered their allocation correctly. At 6 months, 46%, 32% and 41%, respectively, remembered
allocation correctly, and at 12 months correct memory of allocation was still recorded in 41%, 28% and
35% of participants.
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FIGURE 9 Functional outcome of the combined (continuous and nocturnal) oxygen group compared with the
control group at (a) 3; (b) 6; and (c) 12 months post randomisation.
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FIGURE 10 Functional outcome of the continuous oxygen group compared with the nocturnal only oxygen group
at (a) 3; (b) 6; and (c) 12 months post randomisation.
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TABLE 13 Secondary outcomes at 3, 6 and 12 months
Variable
Time point
3 months 6 months 12 months
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Continuous oxygen
(n= 2668)
Nocturnal oxygen
(n= 2667)
Control
(n= 2668)
Death by follow-up
time point
a
257 (10.0%),
n= 2567
236 (9.2%),
n= 2561
246 (9.7%),
n= 2549
280 (11.3%),
n= 2475
269 (10.9%),
n= 2476
272 (11.0%),
n= 2468
285 (12.4%),
n= 2300
269 (11.8%),
n= 2289
279 (12.3%),
n= 2268
Death by 90 days
a
(date)
222 (8.7%),
n= 2566
194 (7.6%),
n= 2565
214 (8.4%),
n= 2550
– – – – – –
Alive and
independent
a
1325 (51.6%),
n= 2567
1316 (51.4%),
n= 2561
1337 (52.5%),
n= 2549
1313 (53.1%),
n= 2475
1305 (52.7%),
n= 2476
1305 (52.9%),
n= 2468
1216 (52.9%),
n= 2300
1178 (51.5%),
n= 2289
1215 (53.6%),
n= 2268
Living at home
a
1961 (85.8%),
n= 2285
1947 (84.8%),
n= 2295
1947 (85.4%),
n= 2279
1910 (87.6%),
n= 2181
1932 (88.0%),
n= 2196
1888 (86.4%),
n= 2184
1774 (88.4%),
n= 2006
1766 (88.0%),
n= 2007
1728 (87.1%),
n= 1983
Barthel ADL index
[0 (worst) to 100
(best)]
b
70.2 (68.7 to 71.8),
n= 2169
71.1 (69.6 to 72.6),
n= 2194
70.9 (69.3 to 72.4),
n= 2186
71.4 (69.9 to 72.9),
n= 2175
70.9 (69.4 to 72.5),
n= 2158
71.1 (69.6 to 72.7),
n= 2158
70.3 (68.6 to 72.0),
n= 1945
70.1 (68.5 to 71.7),
n= 1963
70.7 (69.0 to 72.3),
n= 1954
Nottingham
Extended ADL
[0 (worst) to 21
(best)]
b
9.66 (9.38 to 9.93),
n= 2520
9.54 (9.26 to 9.81),
n= 2501
9.77 (9.49 to 10.05),
n= 2507
9.85 (9.57 to 10.14),
n= 2442
9.74 (9.45 to 10.02),
n= 2442
10.01 (9.72 to 10.30),
n= 2426
10.09 (9.79 to 10.39),
n= 2254
9.80 (9.50 to 10.10),
n= 2239
10.15 (9.84 to 10.45),
n= 2218
Quality of Life
(EQ-5D-3L) [–0.59
(worst) to 1 (best)]
b
0.44 (0.42 to 0.46),
n= 2413
0.44 (0.42 to 0.46),
n= 2428
0.43 (0.41 to 0.45),
n= 2407
0.42 (0.40 to 0.44),
n= 2338
0.43 (0.41 to 0.45),
n= 2353
0.43 (0.40 to 0.45),
n= 2328
0.41 (0.39 to 0.43),
n= 2103
0.42 (0.40 to 0.45),
n= 2110
0.41 (0.39 to 0.44),
n= 2081
Quality of life
(EQ-VAS) [0 (worst)
to 100 (best)]
b
55.4 (54.2 to 56.7),
n= 2251
55.7 (54.4 to 56.9),
n= 2216
55.5 (54.2 to 56.7),
n= 2208
56.9 (55.6 to 58.2),
n= 2164
57.1 (55.8 to 58.4),
n= 2148
56.9 (55.6 to 58.2),
n= 2133
56.1 (54.7 to 57.6),
n= 1900
57.0 (55.6 to 58.4),
n= 1903
56.7 (55.3 to 58.1),
n= 1872
Sleep as good as
before the stroke
a
1407 (64%),
n= 2194
1436 (65%),
n= 2208
1419 (65%),
n= 2182
1339 (64%),
n= 2103
1368 (65%),
n= 2114
1363 (65%),
n= 2100
1249 (66%),
n= 1888
1243 (64%),
n= 1930
1196 (63%),
n= 1889
No significant
speech problems
a
1957 (88%),
n= 2229
1957 (87%),
n= 2246
1939 (87%),
n= 2241
1923 (89%),
n= 2152
1921 (89%),
n= 2163
1900 (89%),
n= 2140
1739 (90%),
n= 1940
1749 (90%),
n= 1954
1750 (91%),
n= 1925
Memory as good
as before the
stroke
a
981 (44%),
n= 2222
1000 (45%),
n= 2224
971 (44%),
n= 2220
888 (42%),
n= 2127
914 (43%),
n= 2132
888 (42%),
n= 2110
800 (42%),
n= 1920
782 (41%),
n= 1930
762 (40%),
n= 1893
ADL, Activities of daily living; EQ-5D-3L, European Quality of Life-5 Dimensions, three levels; VAS, visual analogue scale.
a Data are given as numbers and percentages.
b Data are given as means and 99% CIs.
Alive and independent is a mRS score of two or fewer.
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Co-enrolment in other research studies
Participants in SO2S were permitted to co-enrol in other studies, if they wished, and if other studies were
available. Participants were asked if they were enrolled in other studies at each of the three follow-up
points. The results are shown in Table 16. The proportion of participants who reported enrolment in other
studies was low, with no differences between treatment groups, and did not change over time (3%, 4%
and 3% at 3, 6 and 12 months, respectively).
Safety outcomes
The number of patients who experienced at least one serious adverse event at 90, 180 and 365 days is
shown in Table 17. Details of serious adverse events within the first 90 days are given in Table 18.
Health economics analysis results
A total of 7898 trial participants (no ROS, n = 2629; continuous ROS, n = 2636; and nocturnal ROS,
n = 2633) formed the data set for the analysis. All base-case analyses were conducted on the imputed
data set. The analyses for the comparison of ROS with no ROS are presented first, followed by all analyses
for the comparison of continuous ROS and nocturnal ROS with no ROS and, finally, the deterministic
sensitivity analyses for ROS compared with no ROS.
Base-case analysis
Comparison of routine oxygen supplementation with no routine
oxygen supplementation
Table 19 presents the mean outcomes per patient in terms of hospital stay, home time, EQ-5D-3L scores and
QALYs. Both mean hospital stay and home time were marginally higher in the ROS group, but by less than
half a day. There were no differences in mean EQ-5D-3L scores at 3, 6 and 12 months and the difference in
QALYs was very small, at 0.0004 QALYs, and not significant. Table 20 presents disaggregated mean (SD)
health-care costs per patient for trial oxygen and additional oxygen, acute stay costs, readmissions and
long-term care, as well as total health-care costs. As expected, oxygen treatment costs were higher in the
ROS arm, with all other costs slightly higher for ROS, and £206 (95% CI –£283 to £695) higher overall,
compared with no ROS.
The cost-effectiveness analysis presented in Table 21 shows that it costs an additional £71 to gain a day of
home time. The CUA gave an ICER of £463,338 per QALY gained (Table 22). The cost-effectiveness plane
in Figure 11 demonstrates the uncertainty around both costs and QALY differences, with points in all four
quadrants. The corresponding CEAC in Figure 12 shows a 27% probability of ROS being cost-effective
compared with no ROS if society was willing to pay up to £20,000 per additional QALY, also suggesting
ROS is not cost-effective.
TABLE 14 Length of hospital stay
Length of stay in hospital
Trial arm
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667) Control (N= 2668)
Randomisation to final discharge, mean (SD) 18.6 days (50.9 days) 18.6 days (52.0 days) 18.0 days (56.4 days)
No data, n (%) 233 (9%) 266 (10%) 222 (8%)
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TABLE 15 Details of current abode and readmission data for each of the 3-, 6- and 12-month follow-ups
Variable
Time point
3 months 6 months 12 months
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Where do you live now?
In own home, n (%) 1961 (73.5%) 1948 (73.0%) 1947 (73.0%) 1911 (71.7%) 1932 (72.4%) 1888 (70.8%) 1774 (66.5%) 1766 (66.2%) 1728 (64.8%)
In the home of a relative,
n (%)
86 (3.2%) 79 (3.0%) 62 (2.3%) 78 (2.9%) 69 (2.6%) 61 (2.3%) 67 (2.5%) 54 (2.0%) 56 (2.1%)
In a residential home,
n (%)
62 (2.3%) 63 (2.4%) 73 (2.7%) 57 (2.1%) 57 (2.1%) 75 (2.8%) 54 (2.0%) 53 (2.0%) 72 (2.7%)
In a nursing home, n (%) 70 (2.6%) 114 (4.0%) 111 (4.2%) 97 (3.6%) 114 (4.3%) 120 (4.5%) 92 (3.45%) 118 (4.4%) 109 (4.09%)
In a continuing care home,
n (%)
37 (1.4%) 34 (1.3%) 25 (0.9%) 15 (0.6%) 8 (0.3%) 9 (0.3%) 6 (0.2%) 1 (0.04%) 5 (0.19%)
Not left hospital yet since
stroke, n (%)
60 (2.3%) 50 (2.0%) 43 (1.6%) 7 (0.3%) 4 (0.1%) 12 (0.5%) 1 (0.04%) 2 (0.07%) 1 (0.04%)
Other, n (%) 9 (0.3%) 9 (0.3%) 18 (0.7%) 17 (0.6%) 12 (0.5%) 19 (0.7%) 12 (0.5%) 13 (0.49%) 12 (0.4%)
Withdrawn or no data,
n (%)
383 (14.4%) 370 (14.0%) 389 (14.6%) 486 (18.2%) 471 (17.7%) 484 (18.1%) 662 (24.81%) 660 (24.8%) 685 (25.68%)
Have you been admitted to hospital again for any reason after you were discharged?
Yes, n (%) 379 (14%) 356 (13%) 380 (14%) 456 (17%) 457 (17%) 434 (16%) 540 (20%) 550 (21%) 546 (21%)
No, n (%) 1831 (69%) 1883 (71%) 1850 (69%) 1717 (64%) 1732 (65%) 1743 (65%) 1456 (55%) 1449 (54%) 1423 (53%)
No data, n (%) 458 (17%) 428 (16%) 438 (17%) 495 (19%) 478 (18%) 491 (19%) 672 (25%) 668 (25%) 699 (26%)
If yes, how many times?
Once, n (%) 285 (11%) 272 (10%) 296 (11%) 305 (11%) 322 (12%) 295 (11%) 341 (13%) 358 (13%) 363 (14%)
More than once, n (%) 91 (3%) 80 (3%) 83 (3%) 145 (5%) 131 (5%) 134 (5%) 195 (7%) 186 (7%) 181 (7%)
No data, n (%) 3 (0.1%) 4 (0.1%) 1 (< 0.1%) 6 (0.2%) 4 (0.1%) 5 (0.2%) 4 (0.1%) 6 (0.2%) 2 (0.1%)
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TABLE 16 Patient recollection of trial intervention, participation in other trials and details of who completed the follow-up questionnaires for each follow-up time point
Variable
Time points
3 months 6 months 12 months
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Continuous oxygen
(N= 2668)
Nocturnal oxygen
(N= 2667)
Control
(N= 2668)
Can you remember which of the treatments you were given as part of the trial?
Yes (correct), n (%) 1314 (49%) 942 (35%) 1194 (45%) 1228 (46%) 849 (32%) 1082 (41%) 1084 (41%) 749 (28%) 940 (35%)
Yes (incorrect), n (%) 222 (8%) 530 (20%) 105 (4%) 223 (8%) 588 (22%) 120 (4%) 185 (7%) 515 (19%) 117 (5%)
I do not know, n (%) 545 (21%) 621 (23%) 749 (28%) 537 (20%) 577 (22%) 747 (28%) 515 (19%) 567 (21%) 699 (26%)
No data, n (%) 587 (22%) 574 (22%) 620 (23%) 680 (26%) 653 (24%) 719 (27%) 884 (33%) 836 (32%) 912 (34%)
Have you taken part in any other research trials since the start of this study?
Yes, n (%) 78 (3%) 85 (3%) 87 (3%) 95 (4%) 78 (3%) 116 (4%) 75 (3%) 87 (3%) 98 (4%)
No, n (%) 1870 (70%) 1856 (70%) 1838 (69%) 1815 (68%) 1870 (70%) 1775 (67%) 1711 (64%) 1704 (64%) 1673 (63%)
No data, n (%) 720 (27%) 726 (27%) 743 (28%) 758 (28%) 719 (27%) 777 (29%) 882 (33%) 876 (33%) 897 (33%)
Who completed the questionnaire?
Patient, n (%) 888 (33.3%) 840 (31.5%) 873 (32.7%) 810 (30.4%) 763 (28.6%) 783 (29.3%) 742 (27.8%) 760 (28.5%) 767 (28.8%)
Patient with some help, n (%) 266 (10.0%) 238 (8.9%) 233 (8.7%) 192 (7.2%) 187 (7.0%) 166 (6.2%) 187 (7.0%) 176 (6.6%) 164 (6.1%)
A relative, friend or carer,
n (%)
405 (15.2%) 442 (16.6%) 393 (14.7%) 312 (11.7%) 328 (12.3%) 325 (12.2%) 298 (11.2%) 303 (11.4%) 296 (11.1%)
Researcher over the telephone,
n (%)
657 (24.6%) 692 (26.0%) 720 (27%) 824 (30.9%) 872 (32.7%) 845 (31.7%) 709 (26.6%) 715 (26.8%) 701 (26.3%)
Researcher in hospital clinic,
n (%)
18 (0.7%) 22 (0.8%) 13 (0.5%) 10 (0.4%) 7 (0.3%) 18 (0.7%) 8 (0.3%) 4 (0.1%) 10 (0.4%)
Other, n (%) 15 (0.5%) 17 (0.6%) 16 (0.6%) 12 (0.4%) 12 (0.4%) 13 (0.5%) 12 (0.4%) 18 (0.7%) 6 (0.2%)
No data, n (%) 419 (15.7%) 416 (15.6%) 420 (15.8%) 508 (19.0%) 498 (18.7%) 518 (19.4%) 712 (26.7%) 691 (25.9%) 724 (27.1%)
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
38
TABLE 17 The number (proportion) of patients who experienced at least one serious adverse event
Variable
n
(N= 8003)
Trial arm
Combined oxygen
vs. control, OR
(99% CI)
Combined oxygen
vs. control, p-value
Continuous vs.
nocturnal, OR
(95% CI)
Continuous
vs. nocturnal,
p-value
Continuous oxygen
(N= 2668), n (%)
Nocturnal oxygen
(N= 2667), n (%)
Control
(N= 2668), n (%)
Number of patients
with at least one
SAE by 90 days
964 348 (13%),
n= 2668
294 (11%),
n= 2667
322 (12%),
n= 2668
1.00
(0.83 to 1.20)
1.0 1.21
(0.97 to 1.51)
0.02
Number of patients
with at least one
SAE by 180 days
1385 485 (18%),
n= 2668
442 (17%),
n= 2667
458 (17%),
n= 2668
1.02
(0.86 to 1.19)
0.8 1.12
(0.93 to 1.35)
0.1
Number of patients
with at least one
SAE by 365 days
2034 708 (27%),
n= 2668
675 (25%),
n= 2667
651 (24%),
n= 2668
1.08
(0.94 to 1.25)
0.1 1.07
(0.91 to 1.25)
0.3
SAE, serious adverse event.
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TABLE 18 Serious adverse events by event categories
Variable
Trial arm
Total
(N= 8003)
Continuous oxygen
(N= 2668), n
Nocturnal oxygen
(N= 2667), n
Control
(N= 2668), n
Cardiovascular 54 48 37 139
DVT 4 3 3 10
PE 18 6 9 33
Central nervous system 177 141 178 496
Agitation 3 0 0 3
Anxiety 1 1 2 4
Central nervous system other 3 5 2 10
Cerebral oedema 10 2 6 18
Complication of initial stroke 36 26 23 85
Confusion 2 3 0 5
Dementia 0 0 2 2
Extension of initial stroke 34 32 45 111
Functional symptoms 0 2 0 2
Haemorrhagic transformation 8 8 16 32
Headache 1 3 2 6
Intracerebral bleed 12 8 4 24
Intracranial/extracerebral bleed 1 1 4 6
Recurrent stroke 41 36 42 119
Seizure 10 7 18 35
TIA 13 7 10 30
Vertigo 1 0 0 1
Vomiting 1 0 2 3
Cutaneous 1 0 0 1
Gastrointestinal 15 9 13 37
Genitourinary 11 10 21 42
Haematological 0 1 0 1
Immunological 0 0 0 0
Miscellaneous 40 33 37 110
Respiratory 76 84 97 257
Chest infection 2 4 3 9
Hypoxia 3 1 6 10
Pneumonia 69 78 87 234
Respiratory other 2 1 1 4
Oxygen-related 0 0 0 0
Drying of mucous membranes 0 0 0 0
Respiratory depression 0 0 0 0
Other 30 23 23 76
Total 426 358 418 1202
DVT, deep vein thrombosis; PE, pulmonary embolism.
This table gives the number and categories of serious adverse events reported up to 90 days after randomisation.
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TABLE 19 Mean outcomes per patient by treatment group over 12 months
Variable
Intervention
No ROS (N= 2629) ROS (N= 5269)
Mean hospital stay (days) (95% CI) 18.4 (17.7 to 19) 18.7 (17.9 to 19.5)
Mean home time (days) (95% CI) 313.0 (310.4 to 315.7) 313.4 (310.2 to 136.5)
EQ-5D-3L scores [mean (SD)]
Baseline 0 0
3 months 0.48 (0.38) 0.48 (0.37)
6 months 0.48 (0.37) 0.48 (0.37)
12 months 0.46 (0.37) 0.46 (0.37)
Total QALYs over 12 months 0.4133 (0.31) 0.4137 (0.30)
Difference in QALYs (95% CI) 0.0004 (–0.0139 to 0.0148)
TABLE 20 Mean (95% CI) costs (£) per patient by treatment group over 12 months
Cost category
Intervention
No ROS (N= 2629) ROS (N= 5629)
Trial prescribed oxygen 0.65 (0.42 to 0.94) 72.89 (72.62 to 73.15)
Additional oxygen 5.52 (4.76 to 6.37) 9.40 (8.44 to 10.32)
Total oxygen treatment 6.18 (5.40 to 7.05) 82.29 (81.30 to 83.38)
Acute care costs 5130 (4856 to 5406) 5196 (5008 to 5418)
Readmission 978 (929 to 1032) 986 (951 to 1022)
Stroke care after discharge 6587 (6310 to 6865) 6643 (6447 to 6835)
Total cost 12,702 (12,309 to 13,115) 12,908 (12,619 to 13,183)
Mean difference (95% CI) 206 (–283 to 695)
TABLE 21 Cost-effectiveness analysis
Intervention Mean costs (£) Cost difference (£)
Mean days
of home time
Outcome
difference (days)
ICER (£/day of home
time gained)
No ROS 6.2 – 312.28 – –
ROS 82.3 76.1 313.36 1.08 70.74
TABLE 22 Cost–utility analysis
Intervention Mean costs (£) Cost difference (£) Mean QALYs QALY difference ICER (£/QALY gained)
No ROS 12,702 – 0.4133 – –
ROS 12,908 206 0.4137 0.0004 463,338
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Comparison of continuous routine oxygen supplementation and nocturnal routine
oxygen supplementation with no routine oxygen supplementation
Table 23 presents the mean outcomes per patient in terms of hospital stay, home time, EQ-5D-3L scores
and QALYs for all three trial arms. Mean hospital stay was the greatest in the nocturnal ROS group. Home
time was lowest in the nocturnal ROS group and highest for continuous ROS, by almost 3 days compared
with no ROS. There was almost no difference in mean EQ-5D-3L scores at 3, 6 and 12 months. Overall
QALYs for nocturnal ROS were slightly lower (mean difference –0.0023 QALYs) than for no ROS, and
slightly higher than for continuous ROS (mean difference 0.0032 QALYs), but in both cases differences
were very small and non-significant. Table 24 shows the disaggregated mean (SD) health-care costs per
patient for both trial and additional oxygen, acute stay costs, readmissions and long-term care, as well as
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FIGURE 11 Cost-effectiveness plane for ROS compared with no ROS.
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FIGURE 12 Cost-effectiveness acceptability curve for ROS compared with no ROS.
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total health-care costs. Oxygen treatment costs were highest in the continuous ROS arm, and there were
small differences in other health-care costs between trial arms. Total health care costs were higher in both
ROS arms and highest in the continuous ROS arm, £246 (95% CI –£322 to £814) higher overall compared
with no ROS.
The cost-effectiveness analysis presented in Table 25 shows that nocturnal ROS is dominated by no ROS.
An intervention is dominated if it is more costly but less effective. Here, the outcomes for nocturnal ROS
are worse, with fewer days of home time but at a higher cost than no ROS. Continuous ROS costs £25 per
extra day of home time gained compared with no ROS. In the CUA, nocturnal ROS was again dominated
because of lower QALYs and higher costs. Continuous ROS had an ICER of £76,997 per QALY gained,
well above standard NICE willingness-to-pay thresholds of £20,000 to £30,000 per QALY (Table 26). The
cost-effectiveness plane in Figure 13 displays a high level of uncertainty in both cost and QALY differences,
with points in all four quadrants, and the corresponding CEAC (Figure 14) shows a 31% probability of
continuous ROS being cost-effective compared with no ROS at a £20,000 per additional QALY threshold,
suggesting that it is not a cost-effective intervention.
TABLE 24 Mean (95% CI) costs (£) per participant by treatment group over 12 months
Cost category
Intervention
No ROS (N= 2629)
Nocturnal ROS
(N= 2633)
Continuous ROS
(N= 2636)
Trial prescribed oxygen 0.65 (0.42 to 0.94) 64.32 (64.12 to 64.50) 81.45 (81.21 to 81.67)
Additional oxygen 5.52 (4.76 to 6.37) 3.83 (3.27 to 4.46) 14.97 (13.32 to 16.73)
Total oxygen treatment 6.18 (5.40 to 7.05) 68.15 (67.50 to 68.79) 96.42 (94.61 to 98.26)
Acute care costs 5130 (4855 to 5404) 5125 (4862 to 5406) 5265 (4990 to 5583)
Readmission 978 (929 to 1032) 976 (924 to 1030) 997 (948 to 1052)
Stroke care after discharge 6587 (6310 to 5406) 6697 (6420 to 6984) 6588 (6305 to 6855)
Total cost 12,702 (12,309 to 13,115) 12,867 (12,471 to 13,286) 12,948 (12,523 to 13,347)
Mean difference (95% CI)
(vs. no ROS)
– 165 (–393 to 725) 246 (–322 to 814)
TABLE 23 Mean outcomes per patient by treatment group over 12 months
Variable
Intervention
No ROS (N= 2629)
Nocturnal ROS
(N= 2633)
Continuous ROS
(N= 2636)
Mean hospital stay (days)
(95% CI)
18.4 (17.7 to 19.0) 19.0 (17.9 to 20.1) 18.5 (17.4 to 19.6)
Mean home time (days)
(95% CI)
313.0 (310.4 to 315.7) 310.9 (306.6 to 315.6) 315.9 (311.4 to 320.2)
EQ-5D-3L scores, mean (SD)
Baseline 0 0 0
3 months 0.48 (0.38) 0.48 (0.37) 0.48 (0.37)
6 months 0.48 (0.37) 0.47 (0.37) 0.48 (0.36)
12 months 0.46 (0.37) 0.46 (0.37) 0.46 (0.36)
Mean (SD) total QALYs over
12 months
0.4133 (0.31) 0.4109 (0.31) 0.4164 (0.30)
Difference in QALYs (95% CI)
(vs. no ROS)
– –0.0023 (–0.018 to 0.014)] 0.0032 (–0.0132 to 0.0019)
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TABLE 25 Cost-effectiveness analysis
Intervention
Mean
costs (£)
Cost
difference (£)
Mean days of
home time
Outcome
difference (days)
ICER (£/day of
home time gained)
No ROS 6.2 – 312.28 – –
Nocturnal ROS 68.2 62.0 310.87 –1.41 Dominated
Continuous ROS 96.4 90.2 315.87 3.59 25.13
TABLE 26 Cost–utility analysis
Intervention
Mean
costs (£)
Cost
difference (£) Mean QALYs QALY difference
ICER
(£/QALY gained)
No ROS 12,702 – 0.4133 – –
Nocturnal ROS 12,867 165 0.4109 –0.0023 Dominated
Continuous ROS 12,948 246 0.4164 0.0032 76,997
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FIGURE 13 Cost-effectiveness plane for continuous ROS compared with no ROS.
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Sensitivity analysis
Deterministic sensitivity analysis was undertaken for the CUA for ROS versus no ROS. This was to assess
(1) the impact on results of changing the health care cost inputs and (2) an alternative approach to valuing
baseline quality of life. Three main types of cost (oxygen, acute care, long-term care) were individually
changed by increasing and then decreasing the base-case value by 20% (Table 27). The difference in costs
between ROS and no ROS changed very little across the board and all ICERs were over £400,000 per
QALY gained. The differences in ICERs do appear to be large; however, this is a result of the sensitivity of
the ICER to small changes in cost, owing to the extremely small difference in QALYs.
A further analysis was undertaken to look at the impact of applying a different method for valuing the
baseline quality of life of patients (Table 28). The base-case assumed an EQ-5D-3L score of zero and a
linear increase in quality of life to 3 months. The alternative analysis used the EQ-5D-3L value at 3 months
for the baseline value. This increased the total mean QALYs over 12 months for both ROS and no ROS
and the difference in QALYs also increased to 0.0008, but this is still a very small difference. The ICER
decreased to £257,500 per QALY gained, still considerably higher than the cost per QALY threshold of
£20,000 to £30,000 per QALY.
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FIGURE 14 Cost-effectiveness acceptability curve for continuous ROS compared with no ROS.
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TABLE 27 Sensitivity analysis for costs (£) for the comparison between ROS vs. no ROS
Cost/outcome
Acute care costs
increased by 20%
Acute care costs
decreased by 20%
Total oxygen
treatment cost
increased by 20%
Total oxygen
treatment cost
decreased by 20%
Stroke care after
discharge increased
by 20%
Stroke care after
discharge decreased
by 20%
No ROS ROS No ROS ROS No ROS ROS No ROS ROS No ROS ROS No ROS ROS
Mean cost 13,727 13,946 11,675 11,868 12,702 12,923 12,700 12,891 14,018 14,236 11,384 11,578
Cost difference – 219 – 193 – 221 – 191 – 218 – 194
Mean QALYs 0.4133 0.4137 0.4133 0.4137 0.4133 0.4137 0.4133 0.4137 0.4133 0.4137 0.4133 0.4137
QALY difference – 0.0004 – 0.0004 – 0.0004 – 0.0004 – 0.0004 – 0.0004
Cost per QALY – 493,185 – 433,603 – 497,638 – 429,150 – 488,394 – 438,417
TABLE 28 Sensitivity analysis applying an alternative assumption for baseline EQ-5D-3L score
Intervention Mean costs (£) Cost difference (£) Mean QALYs QALY difference ICER (£/QALY gained)
No ROS 12,702 – 0.4729 – –
ROS 12,908 206 0.4737 0.0008 257,500
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Chapter 4 Discussion
The Stroke Oxygen Study is, with 8003 participants enrolled, the largest UK acute stroke trial. Over 50%of all stroke services in the UK contributed to the study, making participants representative of typical
UK stroke patients. The results of SO2S show that routine low-dose oxygen supplementation after acute
stroke does not improve early neurological recovery or long-term functional outcome. The observed lack
of effect was consistent across all time points (1 week and 3, 6 and 12 months), all outcomes and all
subgroups. There was no difference in outcome between the group given oxygen continuously and the
group that was given oxygen at night only.
In the following sections potential reasons for lack of effect, limitations of the study, health economic
aspects, what SO2S adds to existing evidence, what remains unknown, and implications for treatment and
research will be discussed.
Potential reasons for the observed lack of effect
Mismatch of baseline clinical and demographic characteristics
The large sample size (n = 8003) makes mismatch of baseline clinical characteristics highly unlikely. Further
safeguards against mismatch were built into the protocol. Randomisation by minimisation including key
prognostic factors (age, sex, living alone, normal verbal component of the GCS, ability to lift both arms,
the ability to walk, routine oxygen treatment during ambulance transfer and baseline oxygen saturation)
ensured equal distribution of these factors across the three treatment groups. Effectiveness of minimisation
was monitored continuously during the course of the study via online minimisation reports. The results in
Table 6 confirm that there were no differences in demographics and baseline clinical characteristics
between the three groups. The negative results of this study cannot be explained by a mismatch in
baseline clinical characteristics.
The patients recruited to the study were not representative of acute
stroke patients
To ensure that patients in SO2S were representative of acute stroke patients, inclusion criteria both for
participating centres and for patient enrolment were wide. This is the largest and highest recruiting acute
stroke study in the UK. In total 136 centres, including both acute and hyperacute stroke units, participated
in the study. This means that over 50% of stroke services in the UK enrolled patients into SO2S. Stroke
patients enrolled into clinical studies tend to have less severe neurological deficits than the overall stroke
population unless the inclusion criteria specify that only severe patients can be included. Key reasons for
this are both ethical constraints (it would not be ethical to include moribund patients who have nothing to
gain from the trial intervention) and problems with obtaining informed consent in a patient group who
have suffered a brain injury and are therefore often unable to make a fully informed decision. In spite of
these unavoidable constraints, stroke severity in SO2S was representative of the stroke population in the
UK. Participants in SO2S had a median NIHSS score of 5. While this seems low, it reflects patients admitted
to acute stroke units. Data from 23,199 patients in the UK Sentinel Stroke National Audit Programme
show a median NIHSS score of 4 for stroke patients in the UK.82 The median NIHSS score of 127,950
patients with acute ischaemic stroke in the US Get with the Guidelines Register was 5,83 as in SO2S.
A median NIHSS score of 5 was also recorded at baseline in a recently published Dutch study of antibiotic
prophylaxis after stroke,84 which had similarly wide inclusion criteria to those of SO2S. This is a study of
routine prophylactic oxygen supplementation in acute stroke. Patients with clinically significant hypoxia
(e.g. oxygen saturations below 90%) who thus had indications for oxygen supplementation were not
included. Our results therefore do not apply to clearly hypoxic patients. However, 717 of the participants
had mild hypoxia (oxygen saturation below 95%) at the time of enrolment. The lack of benefit was the
same in this subgroup as in patients who had normal or high-normal oxygen saturations at enrolment.
While this study was not powered to examine this question, the results do not support the hypothesis that
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patients with lower baseline oxygen saturations are more likely to benefit from oxygen treatment. While
we have not conducted formal screening logs for this study, discussions with participating centres about
barriers to recruitment identified the requirement to recruit within 24 hours of hospital admission and
the need for informed consent as the main barriers to enrolment, while clinical indications for oxygen
treatment were rarely a problem. Apart from the protocol-driven exclusion of hypoxic patients, the
participants in this study were as representative of the general stroke patient population as it is possible to
achieve in a clinical study.
The amount of oxygen given may have been insufficient
The dose of oxygen given in SO2S was based on the results of a dose-ranging study and aimed to keep
oxygen saturation within the normal range, avoiding both hyperoxia and hypoxia. The dose of oxygen
given might have been too low. Studies of short-duration high-flow oxygen do not support this possibility
but were too small to identify benefit or exclude harm.30,85 The largest (n = 85) study of short-burst
high-flow oxygen was terminated early because of excess mortality in the actively treated group,86 but it
cannot be excluded that this difference was a result of baseline imbalance in the study groups rather than
a true effect of oxygen. All three studies tested oxygen for 12 hours or less. It remains unknown whether
or not higher-flow oxygen given during the whole hyperacute phase of stroke, as in SO2S, could be
effective, but, given the results so far, this seems unlikely. Indeed, there is increasing concern that
high-dose oxygen treatment could be harmful after stroke and in other forms of neurological injury.
Hyperoxia (PaO2 > 39.99 kPa) was independently associated with mortality in a large retrospective cohort
study of ventilated stroke patients.87 Hyperoxia has also been related to delayed cerebral ischaemia in
patients with subarachnoid haemorrhage (PaO2 > 23.06 kPa),88 to higher mortality and worse functional
outcomes in traumatic brain injury (PaO2 > 26.66 kPa),89 and to increased in-hospital mortality following
resuscitation from cardiac arrest (PaO2 > 39.99 kPa).90 It is therefore highly unlikely that a higher dose of
oxygen would have been more effective.
Oxygen treatment may have been ineffective because of poor compliance
Oxygen treatment can be effective only when it is given as prescribed. It is relatively easy to ensure that
tablets or injections are given and to check compliance, as all drug treatments are recorded in the drug
chart. Oxygen treatment is also prescribed on the drug chart, but given continuously, so that it is not
possible to record compliance at all time points. Acute stroke patients are often confused and restless, and
intentional or accidental removal of the nasal cannulae or oxygen mask is common. Minor benefits from
oxygen treatment might therefore have been masked by poor compliance. Compliance with oxygen
treatment was checked by two methods. Investigators were asked to document whether or not trial
oxygen was prescribed. This was done as instructed in > 99% patients in the oxygen groups. They were
also required to document whether or not the oxygen was actually given. The latter was recorded
unreliably in the drug charts. Oxygen is normally prescribed only once as a continuous treatment, and
nurses were not used to signing for ongoing oxygen treatment as they would for doses of medicines.
To encourage more reliable recording of administration, we instructed centres to circle time points for
signatures in the drug chart and put marks onto each field/time point requiring a signature (four times
daily). In addition, we amended the protocol to require spot checks of compliance with oxygen treatment
at different time points (00:00 and 06:00). This applied to the final 4144 patients. The results showed that
oxygen was administered as prescribed in 65–83% of participants. These spot checks also showed that
3% of the control patients had oxygen in place at midnight and 6 a.m. Prescription of oxygen for clinical
indications was permitted in all three treatment groups, and it was therefore appropriate that a small
proportion of patients in the control group were found to have oxygen in place. While the main analysis
of the study was intention to treat, a sensitivity analysis was conducted to examine the effects of
non-compliance. This confirmed the main results that oxygen treatment, whether given continuously or
at night-time only, did not improve outcome. The OR of the comparison of the combined oxygen groups
with the control group was below 1, suggesting a possibility of harm, rather than benefit. However, this
effect was very small and not significant statistically. It does nevertheless make poor compliance a less
likely reason for ineffectiveness. Furthermore, oxygen treatment increased oxygen saturation in both the
continuous and the night-time only treatment groups. Despite suboptimal compliance, we found highly
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significant increases of 0.8% and 0.9% in the highest and lowest oxygen saturations, respectively, in
the oxygen groups compared with the control group during the intervention. While these changes in
saturation are small, because of the S-shape of the haemoglobin dissociation curve, even small changes
in oxygen saturation can reflect significant differences in the amount of oxygen dissolved in the blood.
The high mean baseline oxygen saturation (96.6%) placed many participants on the flat part of the curve,
where saturation changes little with increasing blood oxygen concentrations. A dose-ranging study of
oxygen supplementation in stroke patients showed a 2.2% increase in oxygen saturation with 2 l/minute
and a 2.9% increase with 3 l/minute.31 In this study patients were observed continuously so that
non-compliance could be excluded. However, the baseline oxygen saturation was lower at 95% and this
will also have contributed to the relatively larger response. SO2S was a pragmatic study and aimed to
reflect clinical practice rather than strictly supervised experimental conditions. Better compliance would
require continuous observation of patients, and this is impracticable outside an intensive care unit.
Few participants in the Stroke Oxygen Study were recorded as being hypoxic
When planning the study we may have overestimated the number of patients who develop hypoxia.
If hypoxia is uncommon, the effect of prophylactic treatment would be diluted. In SO2S very few (1.8%)
participants in either group were recorded as having oxygen desaturations below 90%, with no differences
between groups. In the Stroke Oxygen Pilot Study, 20% of patients in the oxygen group and 33% in the
control group spent > 5 minutes with an oxygen saturation below 90% at night, but only 4% and 5%,
respectively, spent > 60 minutes with an oxygen saturation below 90%.31 Age, baseline oxygen saturation
and NIHSS scores were similar in both studies. In the pilot study, oxygen desaturation was recorded
continuously by pulse oximetry, while in SO2S pulse oximetry readings were taken from intermittent
measurements recorded in the patients’ notes. It is likely that short episodes of hypoxia were missed in
SO2S. This fits with evidence from a meta-analysis of continuous compared with intermittent monitoring of
stroke patients, which also shows that intermittent monitoring detects fewer episodes of hypoxia than
continuous monitoring.91 A study of patients recovering from non-cardiac surgery showed that intermittent
monitoring by ward nurses in a non-intensive care setting missed 90% of hypoxaemic episodes in which
saturation was < 90% for at least 1 hour.92 It is reasonable to assume that intermittent monitoring on
stroke units is no more effective than that.
Neither the Stroke Oxygen Pilot Study nor SO2S found a significant difference in severe desaturations
between the treatment and control groups, which may indicate that low-dose oxygen supplementation is
not sufficient to prevent severe desaturations.31 Intermittent spot checks of oxygen saturation are likely to
miss a significant number of transient episodes of hypoxia. This study was not designed to monitor oxygen
saturation. It is unlikely that the Stroke Oxygen Study population has had fewer episodes of hypoxia than
other stroke populations monitored continuously. It is therefore very unlikely that the lack of effect can be
explained by rarity of hypoxic episodes.
Oxygen may have been started too late to have an effect
In SO2S oxygen treatment was started at a median of 20 hours 43 minutes after symptom onset. This is
well after the hyperacute phase of the stroke. It is therefore not possible to determine from the results of
this study whether or not earlier oxygen treatment might have been more effective. However, other
studies of oxygen treatment after stroke have enrolled patients earlier (Rønning and Guldvog29 within
24 hours, Singhal et al.30 and Singhal 201086 within 8 hours, and Chiu et al.93 within 12 hours), but also
showed no beneficial effect.
Oxygen might still be beneficial, if given to the right subgroup of patients
Subgroup analyses did not identify any class of patient that was more likely to benefit from oxygen
treatment. This included patients enrolled soon after onset of stroke, those with lower baseline oxygen
saturation and patients with more severe strokes, the groups that were expected to be most likely to
benefit from oxygen. However, patients who clearly needed oxygen because of dyspnoea or hypoxia were
not enrolled into the study. The results of SO2S can therefore not be extrapolated to this subgroup.
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Incomplete blinding may have introduced bias
Patients tend to expect benefit from active treatment rather than from control. For oxygen, this may apply
more than for unknown new interventions, as many patients know that the brain needs oxygen and that
oxygen cannot get to the brain when the blood supply is blocked. Giving more thus makes sense
intuitively. Knowing whether or not they have had oxygen could thus have affected their assessment of
recovery. Just under 50% of participants remembered their treatment allocation correctly at 3 months,
reducing with time to 35% at 12 months. Bias towards effectiveness of oxygen treatment cannot be
excluded with an open design. Bias towards assuming a worse outcome with oxygen treatment is very
unlikely. SO2S did not show any effect of active treatment on any of the outcomes. While strong positive
bias of the patients could have masked an adverse effect, this is unlikely. In addition, the lack of effect on
functional outcomes was mirrored by a lack of effect on mortality, and the latter is not subject to bias.
Limitations to the study
Our aim was to test whether or not ROS improves outcome, not whether or not treating manifest hypoxia
is beneficial. We have not included patients who were severely hypoxic (oxygen saturation below 90%) or
had other definite indications for oxygen in the study. Therefore the results of the study do not apply
to patients with severe hypoxia or those with definite indications for oxygen treatment not related to
the stroke.
What does the Stroke Oxygen Study add to existing evidence?
There are two other published studies of low-dose oxygen supplementation after acute stroke.30,85
In contrast to the much smaller Stroke Oxygen Pilot Study,31 we found no evidence of better early
neurological recovery with oxygen. Our results confirm the findings of Rønning and Guldvog,29 who
conducted a much smaller study, and found no overall benefit from oxygen given at 3 l/minute for
24 hours. While their subgroup analysis suggested a possibility of harm from oxygen in mild strokes, we
found no evidence of an adverse effect on outcome in the subgroup of patients with mild strokes or with
TIAs. While our results do not support routine oxygen treatment, they do provide reassurance on its safety.
A search of the literature identifying all randomised controlled studies investigating the effect of routine
normobaric oxygen treatment on functional or neurological outcome in patients with acute stroke using a
series of terms including ‘stroke’, ‘oxygen’ and ‘clinical trial’ up to March 2015 identified four published
studies29–32,85 and one study reporting results online only.86 A total of 979 patients were included. Oxygen
was given in doses ranging from 2 to 45 l/minute and for durations of 8–72 hours. A meta-analysis
was conducted including these and 8003 patients enrolled into SO2S. Statistical heterogeneity for these
studies was moderate (I2 = 31%; Cochran Q; p = 0.21) and study estimates were combined using a
Mantel–Haenszel method in a random-effects model. There was no reduction in mortality at 90 days (or by
the end of follow-up when 90-day outcomes were not available) with oxygen treatment, with an averaged
OR across studies of 1.11 (95% CI 0.84 to 1.46). Oxygen also had no effect on recovery, when reported
(five out of six studies). SO2S provides clear evidence and adequate power to establish that ROS early
after acute stroke does not improve outcome. As SO2S is much larger than earlier trials, the results of the
meta-analysis reflect the outcome of this study. There is no indication from the other studies that giving
oxygen earlier is more beneficial, or that higher doses are more effective. Unpublished results from one
small study suggest that very high doses of oxygen may be associated with higher mortality (Aneesh B
Singhal, Massachusetts General Hospital, 2010, personal communication). Concern about the potential of
excessive doses of oxygen to cause harm has also been raised by a non-randomised observational study
of 2894 ventilated stroke patients treated on intensive care units, for which hyperoxia was associated with
higher mortality than both hypoxia and normoxia.87
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Rapid recruitment and study set-up
The Stroke Oxygen Study is the largest and fastest recruiting stroke study enrolling patients from the UK
only. Recruitment of trial sites and set-up was facilitated by the stroke research network. This study would
not have been possible without the research staff and infrastructure provided by the network.
Health economics
The results of the health economics analysis are in line with the clinical findings, demonstrating that there
is no benefit from offering patients oxygen supplementation in hospital after stroke. The treatment does
not result in significantly higher quality-adjusted survival and neither does it mean that patients return
home more quickly, but it does increase costs of treatment. The point estimates of cost-effectiveness and
the results shown in the CEACs do not suggest that the treatment is cost-effective. When the analysis
considered all three trial treatments, nocturnal ROS was dominated, that is associated with slightly poorer
outcomes but higher costs than no ROS. Continuous ROS resulted in about 3.5 days of home time gained,
but this did not translate into significant QALY gains and the ICER was still well above the £20,000 to
£30,000 NICE willingness-to-pay threshold used by UK NHS decision-makers. The CEAC also demonstrated
a low probability of cost-effectiveness (31%) at £20,000/QALY. Implications for practice are that it should
be recommended that patients do not need to receive oxygen supplementation unless clinically indicated.
This is the first health economics analysis of ROS compared with no ROS in stroke patients, and compared
with many other economic evaluations has a very large sample size, thus increasing confidence in the
robustness of the results. The main limitations of this study relate to data collection. In the majority of
trial-based analyses it is possible to collect baseline quality-of-life data, which are then used in the
calculation of QALYs. However, this data collection is not possible in acute admission for stroke. This
creates problems in calculating QALYs; therefore, assumptions have to be made about the baseline quality
of life. This issue has been explored previously and the methodology has been repeated here: the baseline
quality of life score is assumed to be zero and then quality of life increases linearly to the 3-month score.79
Obviously, patient quality of life trajectories will vary considerably, with some patients recovering very
quickly, thus underestimating QALYs in the first 3 months. An alternative method was used in the analysis,
with the 3-month score also being used for the baseline score. Comparison of the results of the two
methods showed that there was no overall impact on the direction of the results. This remains an area in
which further research is needed on the optimum way of dealing with baseline quality of life where data
collection is not possible.
Detailed data were also not available on patients with regard to date of discharge and destination, or
readmissions. Completion of parts of the patient questionnaires was suboptimal, and data collection on
such a large number of patients also presented logistical difficulties. Therefore, assumptions were required
regarding final discharge destination and an average length of readmission was assumed and an overall
average cost applied, which may result in reducing the overall variability of health-care costs. Finally, the
costs used for long-term care post discharge were obtained from a report from 2002.79 More up-to-date
costs of care for independent and dependent patients were sought; however, scrutiny of the literature did
not yield any costs that were appropriate for this analysis and many economic evaluations in stroke since
2002 have used the same unit costs.
Future work
Post-stroke hypoxia is associated with adverse outcomes after stroke. SO2S has shown that routine low-dose
oxygen supplementation does not improve this. Subgroup analysis has not identified any patient group
more likely to benefit. We cannot exclude that very early enrolment could make a difference, but this was
not supported by results from the small subgroup enrolled within less than 6 hours. We cannot extrapolate
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our results to use of high doses of oxygen, but there is currently no good support from published studies in
humans. Evidence from observational studies suggests that hypoxia, especially if untreated, is associated
with adverse outcomes. Hypoxia is a sign of underlying pathology (e.g. airway obstruction, pneumonia,
heart failure, pulmonary embolism), which requires specific treatment. It is possible that oxygen treatment
delays recognition and thereby also treatment of these complications. Future work should therefore focus
on early detection and/or prevention of hypoxia.
The nature of the trial and large sample size will allow further analyses to be undertaken in the future to
explore important questions regarding outcomes in the first 12 months after stroke. Two further analyses
are planned. First, mean EQ-5D-3L scores will be calculated for groupings of mRS score levels to represent
independence and dependence after stroke. These data will be valuable for use by future decision models
for stroke, allowing the use of patient-reported utility values for model health states. The validity and the
responsiveness of the EQ-5D-3L questionnaire in stroke patients will be explored by comparing responses
with patient scores for the mRS, BI and the NEADL.
Conclusions
In conclusion, the results of SO2S conclusively demonstrate that low-dose oxygen supplementation in
patients who are not severely hypoxic increases oxygen saturation, but is not associated with benefits after
acute stroke in the whole population or in any of the subgroups. The observed lack of benefit is consistent
across all outcomes and all time points up to 1 year, and the same whether oxygen is given continuously
or at night-time only. Results of the health economic analysis confirm the lack of benefit of oxygen in
quality of life and economic terms. Future research should address causes of hypoxia and examine
methods to prevent the development of hypoxia.
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Appendix 1 Participating hospitals and Stroke
Oxygen Study collaborators
Patients were recruited to the SO2S from 136 hospitals across the UK. Hospitals, local principalinvestigators, and numbers recruited per centre are listed according to the number enrolled starting
with the highest recruiting centre.
1. University Hospital of North Staffordshire (C Roffe) (478)
2. St George’s Hospital (B Moynihan) (288)
3. The Royal Liverpool University Hospital (A Manoj) (256)
4. Royal Bournemouth General Hospital (D Jenkinson) (240)
5. Kings College Hospital (L Kalra) (231)
6. Leeds General Infirmary (P Wanklyn) (204)
7. Salford Royal Hospital (C Smith) (191)
8. Southend Hospital (P Guyler) (188)
9. Countess Of Chester Hospital (K Chatterjee) (176)
10. The Royal Victoria Infirmary (A Dixit) (168)
11. Royal Sussex County Hospital (K Ali) (164)
12. Musgrove Park Hospital (M Hussain) (156)
13. Wansbeck Hospital (C Price) (155)
14. Bristol Royal Infirmary (P Murphy) (151)
15. Royal Preston Hospital (S Punekar) (149)
16. University Hospital Aintree (R Durairaj) (148)
17. Birmingham Heartlands Hospital (D Sandler) (143)
18. Pennine Acute (Rochdale) (R Namushi) (134)
19. Queen’s Hospital, Burton (B Mukherjee) (131)
20. University Hospital Coventry (Walsgrave) (P Kanti – Ray) (129)
21. Royal Devon & Exeter Hospital (Wonford) (M James) (113)
22. Royal United Hospital Bath (L Shaw) (113)
23. Royal Cornwall Hospital (Treliske) (F Harrington) (112)
24. Queen Elizabeth The Queen Mother Hospital (G Gunathilagan) (105)
25. York Hospital (J Coyle) (105)
26. University Hospital Of North Durham (B Esisi) (99)
27. Derriford Hospital (A Mohd Nor) (95)
28. Selly Oak Hospital (Acute) (D Sims) (92)
29. St Helen’s & Knowsley Hospitals Trust (V Gowda) (89)
30. Torbay District General Hospital (D Kelly) (88)
31. Charing Cross Hospital (P Sharma) (87)
32. Leighton Hospital (M Salehin) (87)
33. Kent & Canterbury Hospital (I Burger) (84)
34. New Cross Hospital (K Fotherby) (84)
35. Northwick Park Hospital (D Cohen) (83)
36. Barnsley District General Hospital (M Albazzaz) (82)
37. Blackpool Victoria Hospital (J Mcilmoyle) (82)
38. Princess Royal University Hospital (L Sztriha) (81)
39. Eastbourne District General Hospital (C Athulathmudali) (76)
40. Warrington Hospital (K Mahawish) (75)
41. City Hospitals Sunderland (N Majmudar) (69)
42. William Harvey Hospital (Ashford) (D Hargroves) (69)
43. Stepping Hill Hospital (A Krishnamoorthy) (66)
44. The James Cook University Hospital (D Broughton) (66)
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45. Northampton General Hospital (Acute) (M Blake) (59)
46. Leicester General Hospital (A Mistri) (57)
47. Rotherham District General Hospital (J Okwera) (56)
48. St Peter’s Hospital (R Nari) (56)
49. Macclesfield District General Hospital (M Sein) (55)
50. Manor Hospital (K Javaid) (54)
51. Bradford Royal Infirmary (C Patterson) (53)
52. Luton & Dunstable Hospital (L Sekaran) (50)
53. Royal Blackburn Hospital (N Goorah) (50)
54. University College Hospital (R Simister) (50)
55. North Tyneside General Hospital (C Price) (48)
56. Addenbrooke’s Hospital (E Warburton) (48)
57. Queen Alexandra Hospital (D Jarrett) (47)
58. North Devon District Hospital (M Dent) (45)
59. Pilgrim Hospital (D Mangion) (44)
60. Solihull Hospital (K Elfandi) (44)
61. Norfolk & Norwich University Hospital (N Shinh) (41)
62. Gloucestershire Royal Hospital (D Dutta) (40)
63. Royal Surrey County Hospital (A Blight) (39)
64. Southport & Formby District General Hospital (P McDonald) (39)
65. Bishop Auckland General Hospital (A Mehrzad) (35)
66. Airedale General Hospital (E AdbusSammi) (34)
67. Calderdale Royal Hospital (P Rana) (34)
68. Doncaster Royal Infirmary (D Chadha) (34)
69. East Surrey Hospital (B Mearns) (34)
70. Medway Maritime Hospital (S Sanmuganathan) (34)
71. Royal Derby Hospital (T England) (33)
72. Wycombe General Hospital (M Burn) (33)
73. Princess Royal Hospital (R Campbell) (32)
74. Harrogate District Hospital (S Brotheridge) (30)
75. Peterborough City Hospital (P Owusu-Agyei) (30)
76. West Cumberland Hospital (O Orugun) (30)
77. Colchester General Hospital (R Saksena) (29)
78. Royal Hampshire County Hospital (N Smyth) (29)
79. Dorset County Hospital (H Prosche) (27)
80. Frimley Park Hospital (B Clarke) (27)
81. Royal Hallamshire Hospital (M Randall) (27)
82. Yeovil District Hospital (K Rashed) (25)
83. Poole General Hospital (S Ragab) (24)
84. Frenchay Hospital (N Baldwin) (22)
85. Princess Alexandra Hospital (S Hameed) (22)
86. West Suffolk Hospital (A Azim) (22)
87. The Ulster Hospital (M Power) (21)
88. Watford General Hospital (D Collas) (21)
89. Southampton General Hospital (N Weir) (20)
90. Craigavon Area Hospital (M McCormick) (19)
91. Royal Lancaster Infirmary (P Kumar) (18)
92. Basildon Hospital (R Rangasamy) (17)
93. City Hospital Birmingham (S Kausar) (17)
94. Nottingham University Hospitals (A Shetty) (16)
95. Antrim Area Hospital (J Vahidassr) (15)
96. Pinderfields General Hospital (P Datta) (15)
97. Royal Albert Edward Infirmary (S Herath) (15)
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98. Good Hope Hospital (E Smith) (14)
99. Hereford County Hospital (C Jenkins) (13)
100. South Tyneside District General Hospital (J Scott) (13)
101. Broomfield Hospital (V Umachandran) (12)
102. Wythenshawe Hospital (E Gamble) (11)
103. Warwick Hospital (B Thanvi) (10)
104. Ipswich Hospital (J Ngeh) (9)
105. Kettering General Hospital (K Ayres) (9)
106. Nevill Hall Hospital (B Richard) (9)
107. Scarborough General Hospital (J Paterson) (9)
108. Hull Royal Infirmary (A Abdul-Hamid) (8)
109. King’s Mill Hospital (M Cooper) (8)
110. The Royal London Hospital (P Gompertz) (8)
111. Trafford General Hospital (S Musgrave) (8)
112. Altnagelvin Area Hospital (J Corrigan) (7)
113. Darent Valley Hospital (P Aghoram) (7)
114. Royal Berkshire Hospital (A Van Wyk) (6)
115. Arrowe Park Hospital (R Davies) (5)
116. Basingstoke and North Hampshire Hospital (E Giallombardo) (5)
117. Lincoln County Hospital (S Leach) (5)
118. Hexham General Hospital (C Price) (4)
119. Manchester Royal Infirmary (J Simpson) (4)
120. Salisbury District Hospital (T Black) (4)
121. Mayday University Hospital (E Lawrence) (3)
122. Russells Hall Hospital (A Banerjee) (3)
123. Worthing Hospital (S Ivatts) (3)
124. Bedford Hospital (A Elmarimi) (2)
125. James Paget Hospital (M Zaidi) (2)
126. St Richard’s Hospital (S Ivatts) (2)
127. Erne Hospital (J Kelly) (1)
128. University Hospital Lewisham (M Patel) (1)
129. Bronglais General Hospital (P Jones) (0)
130. Hillingdon Hospital (A Parry) (0)
131. Kingston Hospital (L Choy) (0)
132. Morriston Hospital (M Wani) (0)
133. North Middlesex Hospital (R Luder) (0)
134. St Helier Hospital (V Jones) (0)
135. Staffordshire General Hospital (A Oke) (0)
136. The Princess Royal Hospital (K Ali) (0)
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Appendix 2 The case report form
STEP 1  ELIGIBILITY FOR TRIAL INCLUSION 
Time since admission with a clinical diagnosis of stroke (WHO criteria) less than 24h YES NO 
Time since stroke onset less than 48 h YES NO 
Expected to die within  1 year from a non-stroke related illness YES NO 
Definite indication for continuous oxygen treatment YES NO 
Definite contraindication to continuous oxygen treatment YES NO 
Please proceed to patient details if all answers are in the shaded boxes. 
 
STEP 2 PATIENT DETAILS 
Date and time of stroke onset                                                        dd-mon-yyyy                                      hh:mm 
(24 h clock) 
Oxygen given in the ambulance            no / not known / yes   
(for yes specify: 24% mask  / 28% mask / 35% mask / 40% >40% mask /  2L/min via nasal cannula / 3L/min 
via nasal cannula /  4 L/min via nasal cannula/  >4l/min via nasal cannula) 
Oxygen given after arrival in hospital     no / not known / yes  
 (for yes specify: 24% mask  / 28% mask / 35% mask / 40% >40% mask /  2L/min via nasal cannula / 3L/min  
via nasal cannula /  4 L/min via nasal cannula/  >4l/min via nasal cannula) 
Medical History 
Chronic obstructive airways disease or asthma [by history or from list of drugs] YES NO 
Other chronic lung problem [e.g. kyphoscoliosis, thoracoplasty, pneumoconiosis] YES NO 
Heart failure [by history, exam  or >20 mg furosemide or equivalent per day] YES NO 
Ischaemic heart disease [history of angina or MI or treatment with nitrates or nicorandil] YES NO 
Atrial fibrillation YES NO 
 
Glasgow Coma Scale (please circle one response in each row) 
Eye opening None (1) To pain  (2) To speech (3) Spontaneous (4)   
Motor 
Response 
None (1) Extension (2) Abnormal  
flexion (3) 
Withdrawal (4) Localizes  
to pain (5) 
Obeys  
commands (6) 
Verbal resp. None (1) Incomprehensible (2) Inappropriate (3) Confused (4) Oriented (5)  
   
STEP 3  PROGNOSTIC FACTORS (please circle the yes or no and complete oxygen saturation) 
1.1 Age (no need to enter here, will be calculated from DOB and date of stroke) 
1.2  Living alone before the stroke YES NO 
1.3  Independent in activities of daily living before the stroke YES NO 
1.4  Normal verbal response to questions (e.g. verbal Glasgow coma Scale Score=5) YES NO 
1.5  Able to lift the affected arm against gravity YES NO 
1.6  Able to walk unaided YES NO 
2.    Oxygen  treatment prior to randomisation (ambulance or emergency department)  YES NO 
3.    Oxygen saturation on room air at randomisation  ____ % 
4.    Blood glucose (result of BM stick suffices) ____ mmol/l   or _______ g/dl  
Identification  sticker or 
Name  
Sex      male / female 
DOB    DD MON YYYY 
Unit No /Hiss No   
Stroke Oxygen Study  
Randomisation Form  
 
Trial Centre name   
Investigator name    
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STEP 4 NIH Stroke Scale  
1a Level of 
(LOC) 
0 
1 
2 
 
3 
Alert – keenly responsive 
Drowsy – arousable by minor stimulation to obey, answer, or respond 
Stuporous – requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make 
movements (not stereotyped) 
Comatose – responds only with reflex motor or autonomic effects or totally unresponsive, flaccid 
1b LOC 
Questions 
0 
1 
2 
Answers both correctly 
Answers one correctly 
Both incorrect or no reply 
1c LOC 
Commands
0 
1 
2 
Obeys both correctly 
Obeys one correctly 
Both incorrect or no reply 
2. Best Gaze 
0 
1 
2 
Normal 
Partial gaze palsy – gaze is abnormal in one or both eyes, no forced deviation/total gaze paresis  
Forced deviation – or total gaze paresis not overcome by oculocephalic maneouvre 
3. Visual Fields 
0 
1 
2
3 
No visual loss (or in coma) 
Partial hemianopia 
Complete hemianopia
Bilateral Hemianopia – including cortical blindness 
4. Facial Palsy 
0 
1 
2 
3 
Normal 
Minor -  flattened nasolabial fold, asymmetry on smiling 
Partial – total or near total paralysis of lower face 
Complete -  absent facial movement in upper and lower face on one or both sides 
5/6  Best Motor 
ARM 
Right Left  
0 0 No drift – holds limb at 90 degrees for full 10 seconds 
1 1 Drift -  drifts down but does not hit bed 
2 2 Some effort against gravity 
3 3 No effort against gravity 
4 4 No movement 
7/8. Best Motor 
LEG
Right Left  
0 0 No drift – holds limb at 45 degrees for full 5 seconds 
1 1 Drift -  drifts down but does not hit bed 
2 2 Some effort against gravity 
3 3 No effort against gravity 
4 4 No movement 
9. Limb Ataxia 
0 
1 
2 
Absent (or in coma) 
Present in 1 limb 
Present in 2 or more limbs 
10. Sensory 
0 
1 
2 
Normal  
Partial loss – patient feels pinprick is less sharp or is dull on affected side 
Dense loss (or in coma) -  patient is unaware of being touched on face, arm, leg 
11. Best 
Language 
0 
1 
 
 
2 
 
3 
No dysphasia 
Mild – moderate dysphasia  obvious loss of fluency or comprehension, without significant limitation on ideas expressed or 
form of expression. Makes conversation about provided material difficult or impossible, e.g. examiner can identify picture or 
naming card from patient's response. 
Severe dysphasia - all communication is through fragmentary expression; great need for inference, questioning, and guessing 
by the listener who carries burden of communication. Examiner cannot identify materials provided from patient response 
Mute  no usable speech or auditory comprehension, or in coma. 
12. Dysarthria 
0 
1 
2
 
 
Normal articulation 
Mild – moderate dysarthria - patient slurs some words, can be understood with some difficulty. 
Unintelligible or worse - speech is so slurred as to be unintelligible (absence of or out of proportion to dysphasia) or is 
mute/anarthric, or in coma 
 
13. Neglect 
0 
1 
 
2 
No neglect (or in coma) 
Partial neglect - Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in  
one of the sensory modalities 
Complete neglect - Profound hemi-inattention or hemi-inattention to more than one modality. Does not recognise own hand 
or orients to only one side of space 
Total:    
 
Patient is asked to state the month & his/her age 
Patient is asked to open & close eyes, grip & release normal hand 
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STEP 5 CONTACT likely or preferred location for week 1 follow-up  
 
Clinic   
Home   
Hospital same as randomizing centre  
Hospital different to randomizing centre – please give name                                   
Other ________________  
 
STEP 6 CONSENT
 
1. Fully informed consent YES NO 
2. Patient does not disagree  with trial YES NO 
3. Consent from next of kin YES NO 
 
 
STEP 7 RANDOMISATION  via http://www.so2s.co.uk  or (day) or  (after 
hours) 
 
 
Date and time of randomisation                                                   dd-mon-yyyy        hh:mm  
(24 h clock) 
Randomisation number                                      Print Name                                       Sign and Date                                         
 
Monitor oxygen saturation 30 minutes after the start of treatment and 6 hourly thereafter.   
Before randomisation either 1 
OR 2 and 3 must be answered as YES 
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Stroke Oxygen Study    Week 1 (Assessment form) 
 
Name       Randomisation no 
Home 
address:___________________________________________________________ 
 
Home telephone no:   ______________________      NHS number   
 
Has the patient died?    yes / no        Date of death         DD MON 
YYYY  
Please complete the Notification of Death Form (form 3) if the patient is deceased.  
 
Has the patient had serious adverse events? If yes, please complete SAE form (form 
4)   yes /  no  
 
Oxygen administration for clinical indications during the 72 hour trial period: 
 The patient was prescribed or received continuous oxygen for clinical indications 
 The patient was not prescribed or given continuous oxygen for clinical reasons 
outside 
      the trial treatment 
 
Compliance with oxygen treatment as prescribed for this study: 
 Oxygen prescribed for 3 nights and signed in the drug chart as instructed 
 Oxygen prescribed for 3 nights, but not signed as instructed  
      (please 
explain_____________________________________________________________)  
 Oxygen prescribed for 72 hours and signed as instructed 
 Oxygen prescribed for 72 hours and not signed as instructed  
       (please 
explain_____________________________________________________________)  
 Oxygen stopped before the end of 3 days/nights (give reason) 
       Reason for not completing prescribed oxygen 
treatment__________________________ 
 Patient is on the control group (no trial oxygen prescribed) 
 
 
Clinical data during the first week after trial inclusion: 
Antibiotics prescribed after randomization  YES NO 
Thrombolysis performed YES NO 
Sedatives or antipsychotic drugs prescribed after randomizaton YES NO 
Highest temperature during week 1  
 
Other clinical trials: 
Has the patient been enrolled in any other clinical trials?                   YES   /  
NO 
If yes, please specify give name of trial:  
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Record of oxygen saturation and treatment during the first 3 days  
Please check compliance with treatment daily and make sure night staff is aware of 
the study and assessments if saturation or oxygen treatment has not been documented 
as instructed.   
 
Day 1 
Oxygen saturation at 24:00 (midnight) night 1  
Oxygen is in place at 24:00 YES  /  NO  
Oxygen saturation at 6 am night 1  
Oxygen is in place at 06:00 YES  /  NO  
Day 2 
Oxygen saturation at 12:00 (lunchtime) day 2  
Oxygen saturation at 24:00 (midnight) night 2  
Oxygen is in place at 24:00 YES  /  NO  
Oxygen saturation at 6 am night 2  
Oxygen is in place at 06:00 YES  /  NO  
Day 3 
Oxygen saturation at 12:00 (lunchtime) day 3  
Oxygen saturation at 24:00(midnight) night 3  
Oxygen is in place at 24:00 YES  /  NO  
Oxygen saturation at 6 am night 3  
Oxygen is in place at 06:00 YES  /  NO  
 
The highest oxygen saturation during the 3 days of trial treatment   
The lowest oxygen saturation during the 3 days of trial treatment  
The highest heart rate during the 3 days of trial treatment   
The highest systolic blood pressure during the 3 days of trial treatment  
The highest diastolic blood pressure during the 3 days of trial treatment  
 
CT /MRI diagnosis (please tick one of the boxes) 
 Cerebral infarct 
 Primary intracerebral haemorrhage 
 Subdural haemorrhage 
 Subarachnoid haemorrhage 
 Brain tumour 
 Head scan not performed 
 Other (please specify) _______________________________ 
 
Second CT head scan (if performed) date (dd-mon-yyyy)_______      New 
haemorrhage Yes / no 
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Final diagnosis (Please make a final diagnosis using the clinical presentation, time 
course, head scan. Tick only one of the boxes) 
 Ischaemic stroke  
 TIA 
 Primary intracerebral haemorrhage 
 Cerebrovascular accident without CT confirmation of aetiology 
 Other (Please specify) _____________________________ 
 
Date of discharge ……………….. (DD-MON-YYYY) 
If this is not available at the day 7 follow-up please complete once patient has been 
discharged. 
 
Discharge location (If this is not available at the day 7 follow-up please complete 
once patient has been discharged): 
 Patients own home 
 Home of a relative 
 Residential home 
 Nursing home 
 Another hospital – please provide name ……………….. 
 Other ……………….. 
 
Pre-Stroke Rankin 
This is to be completed by the researcher with the either the patient, a relative or 
carer in relation to how the patient was before the stroke (i.e. based on the day before  
the stroke). 
 
 No symptoms at all 
 Few symptoms, but able to carry out usual activities as normal 
 Unable to carry out all usual activates, but can look after own affairs 
without assistance 
 Need some help with looking after own affairs, but can walk without 
assistance 
 Unable to walk or attend bodily needs without assistance, but constant care 
not needed 
 Major symptoms that severely handicap. Bedridden, incontinent and 
require constant attention day and night 
 
Completed by: 
 Patient 
 Other, please specify _________ 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Pre-stroke EQ – 5D 
This is to be completed by the researcher with the either the patient, a relative or 
carer in relation to how the patient was before the stroke (i.e. based on the day before  
the stroke). 
 
Mobility - Please tick the box which best describes the patients level of mobility 
before the stroke 
 I had no problems walking 
 I had some problems walking 
 I was confined to bed 
 
Self care - Please tick the box which best describes the patients ability to care for 
themselves before the stroke  
 I had no problems with self care 
 I had some problems washing and dressing 
 I was unable to wash or dress myself 
 
Usual activities - Please tick one box next to the statement which best describes their 
ability to perform their usual activities before the stroke 
 
 I was able to perform my usual activities 
 I has some problems performing my usual activities 
 I was unable to perform my usual activities 
 
Pain or discomfort - Please tick one box next to the statement which best describes 
their level of pain or discomfort before the stroke 
 
 I had no pain or discomfort 
 I had moderate pain or discomfort 
 I had extreme pain or discomfort 
Anxiety and depression - Please tick one box next to the statement which best 
describes their level of anxiety and depression before the stroke 
 I was not anxious or depressed 
 I was moderately anxious or depressed 
 I was extremely anxious or depressed 
 
Completed by: 
 Patient 
 Other, please specify _________
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NIH Stroke Scale  
1a Level of 
(LOC) 
0 
1 
2 
 
3 
Alert – keenly responsive 
Drowsy – arousable by minor stimulation to obey, answer, or respond 
Stuporous – requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make 
movements (not stereotyped) 
Comatose – responds only with reflex motor or autonomic effects or totally unresponsive, flaccid 
1b LOC 
Questions 
0 
1 
2 
Answers both correctly 
Answers one correctly 
Both incorrect  or  no reply 
1c LOC 
Commands 
0 
1 
2
Obeys both correctly 
Obeys one correctly 
Both incorrect or no relpy
2. Best Gaze 
0 
1 
2 
Normal 
Partial gaze palsy – gaze is abnormal in one or both eyes, no forced deviation/total gaze paresis  
Forced deviation – or total gaze paresis not overcome by oculocephalic maneouvre 
3. Visual Fields 
0 
1 
2 
3 
No visual loss (or in coma) 
Partial hemianopia 
Complete hemianopia 
Bilateral Hemianopia – including cortical blindness 
4. Facial Palsy 
0 
1 
2 
3 
Normal 
Minor -  flattened nasolabial fold, asymmetry on smiling 
Partial – total or near total paralysis of lower face 
Complete -  absent facial movement in upper and lower face on one or both sides 
5/6  Best Motor 
ARM 
Right Left  
0 0 No drift – holds limb at 90 degrees for full 10 seconds 
1 1 Drift -  drifts down but does not hit bed 
2 2 Some effort against gravity 
3 3 No effort against gravity 
4 4 No movement 
7/8. Best Motor 
LEG 
Right Left  
0 0 No drift – holds limb at 45 degrees for full 5 seconds 
1 1 Drift -  drifts down but does not hit bed 
2 2 Some effort against gravity 
3 3 No effort against gravity 
4 4 No movement 
9. Limb Ataxia 
0 
1 
2 
Absent (or in coma) 
Present in 1 limb 
Present in 2 or more limbs 
10. Sensory 
0 
1 
2 
Normal  
Partial loss – patient feels pinprick is less sharp or is dull on affected side 
Dense loss (or in coma) -  patient is unaware of being touched on face, arm, leg 
11.Best 
Language 
0 
1 
 
 
2 
 
 
3 
No dysphasia 
Mild – moderate dysphasia  obvious loss of fluency or comprehension, without significant limitation on ideas expressed or 
form of expression. Makes conversation about provided material difficult or impossible, e.g. examiner can identify picture or 
naming card from patient's response. 
Severe dysphasia - all communication is through fragmentary expression; great need for inference, questioning, and guessing 
by the listener who carries burden of communication. Examiner cannot identify materials provided from patient response 
Mute  no usable speech or auditory comprehension, or in coma. 
12. Dysarthria 
0 
1 
2 
 
 
Normal articulation 
Mild – moderate dysarthria - patient slurs some words, can be understood with some difficulty. 
Unintelligible or worse - speech is so slurred as to be unintelligible (absence of or out of proportion to dysphasia) or is 
mute/anarthric, or in coma 
 
13. Neglect 
0 
1 
 
2 
No neglect (or in coma) 
Partial neglect - Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in  
one of the sensory modalities 
Complete neglect - Profound hemi-inattention or hemi-inattention to more than one modality. Does not recognise own hand 
or orients to only one side of space 
Total  
 
 
 
Patient is asked to state the month & his/her age 
Patient is asked to open & close eyes, grip & release normal hand 
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TOAST criteria (complete for infarcts only) 
 
 Large-artery atherosclerosis (LAA) 
         (tick this if there is Imaging evidence of >50% stenosis of intracranial or extracranial 
artery) 
 Cardioembolism (CE) 
        (Evidence of a medium-risk cardiac source of embolism and no other cause of stroke) 
 
 Small-artery occlusion (lacunar infarct) 
        (Clinically lacunar syndrome and lacunar infarct on CT and no evidence for ipsilat. LAA 
or CE) 
 
 Acute ischaemic stroke of other determined aetiology 
         (rare causes of stroke, such as nonatherosclerotic vasculopathies, hypercoagulable 
states, or  
          haematological disorders and no evidence for LAA or CE ) 
         
 Ischaemic stroke of undetermined aetiology 
         (any patient who does not fit the above, e.g. fully investigated patients with >1 potential 
cause 
         of stroke or patients who have not been fully investigated) 
 
Large-artery atherosclerosis (LAA) 
These patients will have clinical and brain imaging findings of either significant (>50%) stenosis or 
occlusion of a major brain artery or branch cortical artery, presumably due to atherosclerosis.   Clinical 
findings include those of cerebral cortical impairment (aphasia, neglect, restricted motor involvement, 
etc.) or brain stem or cerebellar dysfunction.   A history of intermittent claudication, transient ischaemic 
attacks (TIAs) in the same vascular territory, a carotid bruit, or diminished pulses helps support the 
clinical diagnosis.   Cortical or cerebellar lesions and brain stem or subcortical hemispheric infarcts 
greater than 1.5cm in diameter on CT or MRI are considered to be of potential large-artery 
atherosclerotic origin.   Supportive evidence by duplex imaging or arteriographay of a stenosis of greater 
than 50% of an appropriate intracranial or extracranial artery is needed.   Diagnostic studies should 
exclude potential sources of cardiogenic embolism.   The diagnosis of stroke secondary to large-artery 
atherosclerosis cannot be made if duplex or arteriographic studies are normal or show only minimal 
changes. 
 
Cardioembolism (CE) 
This category includes patients with arterial occlusions presumably due to an embolus arising in the 
heart.   Cardiac sources are divided into high-risk and medium-risk groups based on the evidence of 
their relative propensities for embolism.  At least one cardiac source for an embolus must be identified 
for a possible or probable diagnosis of cardioembolism stroke.   Clinical and brain imaging finding are 
similar to those described for large-artery atherosclerosis.   Evidence of a previous TIA or stroke in more 
than one vascular territory or systemic embolism supports a clinical diagnosis of cardiogenic stroke.   
Potential large-artery atherosclerotic sources of thrombosis or embolism should be eliminated.   A stroke 
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in a patient with a medium-risk cardiac source of embolism and no other cause of stroke is classified as 
a possible cardioembolic stroke. 
 
Small-artery occlusion (lacunar infarct) 
This category includes patients whose strokes are often labelled as lacunar infarcts in other 
classifications.   The patient should have one of the traditional clinical lacunar syndromes and should 
not have evidence of cerebral cortical dysfunction.   A history of diabetes mellitus or hypertension 
supports the clinical diagnosis.   The patient should also have a normal CT/MRI or examination or a 
relevant brain stem or subcortical hemispheric lesion with a diameter of less than 1.5 cm demonstrated.   
Potential cardiac sources for embolism should be absent and evaluation of the large extracranial 
arteries should not demonstrate a stenosis of greater than 50% in an ipsilateral artery. 
 
Acute ischaemic stroke of other determined etiology  
This category includes patients with rare causes of stroke, such as nonatherosclerotic vasculopathies, 
hypercoagulable states, or hematologic disorders.   Patients in this group should have clinical and CT or 
MRI findings of an acute ischaemic stroke, regardless of the size or location.   Diagnostic studies such 
as blood tests or arteriography should reveal one of those unusual causes of stroke.   Cardiac sources 
of embolism and large-artery atherosclerosis should be excluded by other studies. 
 
Ischaemic stroke of undetermined aetiology 
In several instances, the cause of a stroke cannot be determined with any degree of confidence.   Some 
patients will have no likely aetiology determined despite an extensive evaluation.   In others, no cause is 
found but the evaluation was cursory.   This category also includes patients with two or more potential 
causes of stroke so that the physician is unable to make a final diagnosis.  For example, a patient with a 
medium-risk cardiac source of embolism who also has another possible cause of stroke identified would 
be classified as having a stroke of undetermined aetiology.   Other examples would be a patient who 
has atrial fibrillation and an ipsilateral stenosis of 50%, or the patient with a traditional lacunar syndrome 
and an ipsilateral carotid stenosis of 50%. 
 
Completed by : Print Name                                       Sign and Date          
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 Stroke Oxygen Study 
          Week 1 (Contact form) 
 
 
For patients who were incompetent to sign consent at recruitment: 
Competent to sign today?            Yes  
No 
If yes, explain study again and ask patient to sign patient confirmation of consent 
(after recovery)  form. 
 
Preferred contact address and telephone number for the follow-up 
questionnaires: 
Name: 
Street and Number: 
Town, County, country:  
Postcode: 
Tel No:    
Mobile no:                             
 
Alternative contact address and tel number if preferred address cannot be 
contacted: 
Name: 
Street and Number: 
Town, County, country:  
Postcode: 
Tel No:    
Mobile no:                             
 
Address and telephone number of the patient's general practitioner: 
Name of GP: 
Street and Number: 
Town, County, country:  
Postcode: 
Tel No:    
Fax:                             
 
 
Alternative follow-up arrangements if the patient is unable to complete the 3, 6 or 12 
month questionnaire or prefers a personal appointment: 
 
 Clinic Appointment 
 Other 
 
_____________________________________________________________________
___ 
Please complete on line or fax the week 1 assessment form the week 1 contact 
form and the NIHSS score sheet for randomisation and week 1 to  
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Completed by : Print Name                                       Sign and Date          
  
Stroke Oxygen Study 
 
Notification of Death (Assessment Form 3) 
 
 
 
Name                        Randomisation number:   
 
 
Date of Death 
 
 
 
Has the cause of death been confirmed by autopsy?    Yes  No 
 
 
 
 
 
Likely cause of death (tick one box only) 
 
 Neurological damage due to the initial stroke 
 
 Recurrent stroke 
 
 Pneumonia 
 
 Other infection 
 
 Pulmonary Embolism 
 
 Ischaemic heart disease 
 
 Other cause of death (please specify) _______________________________ 
  
 
 
Completed by : Print Name                                       Sign and Date          
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Stroke Oxygen Study 
Serious Adverse Event Notification (Assessment Form 4) 
 
        Please complete form below and fax to                       and  
ASAP within 24 hours of becoming aware of the event. 
 
Trial name: The Stroke Oxygen Study       
ISRCTN52416964                                                                     
 
Report date and time (dd-mon-yyyy  hh:mm) 
____________________________________________________ 
Date of Enrolment _______________Adverse Event date and time (dd-mon-yyyy  hh:mm) 
_______________ 
Centre name 
________________________Country________________________________________________ 
 
Randomisation number ______________    Age (years) _____________     Sex:  Male/female  
 
 
Event information 
When did this event happen with regard to the treatment phase?  Before / During / After 
Is it a Serious adverse event?  
 
An adverse event is defined as serious if any of A-F has been answered with yes. Please describe the event regardless 
of your answer to A-F.  If the answer to questions A-F is ‘no’ in every case this is not a serious event - Please 
complete form (R & D-RF-SOS-001) 
A.  Did the event result in death?  Yes / No 
B.  Is / was the event life threatening?  Yes / No 
C.  Did / does the event lead to hospitalization or prolonged hospitalization?  Yes / No 
D.  Did / does the event result in persistent or significant disability / incapacity?  Yes / No 
E.  Did / does the event result in congenital anomaly / birth defect / carcinogenesis?  
Yes / No 
F.  Does the investigator consider the event a serious adverse event for other reasons  
Yes / No 
 
A1  Nature of event Single   Multiple Episodes 
        Intensity of event / Grading of Serious Adverse Event 
 
Mild  
Moderate  
Severe 
A2  Relationship to study drug(s) / Attribution of Serious Adverse Event 
 
Definitely not Possibly 
Unrelated Probably 
Unlikely   Definitely   
  Unknown 
A3  Action taken regarding study drug(s) 
 
None  Dose(s) missed 
  Discontinued 
A4  Clinical outcome 
 
Recovered  Not Yet Recovered 
  Died 
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B.  Please describe the event in detail, providing any relevant medical information. i.e. pathology, radiology, ECG, 
bacteriology, biochemistry or clinical reports / information. 
If the patient has been re-admitted to hospital please provide re-admission date, discharge date and length of stay 
(days) 
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C.   Assessment of event by local Investigator 
C1.  SAE category as adjudicated by local investigator 
(see attached SAE event categories for guidance) 
 
 
 
C2. Do you consider this SAE unexpected i.e. a Suspected Unexpected Serious 
Adverse Reaction (SUSAR)? 
 
Yes / No 
Form submission sign off - Enter your NAME: 
 
 
 
Date SAE Reported  
Time (24 hour clock) SAE Reported  
Have you checked that all entries above are correct?  Yes / No 
 
D.  Assessment by the Chief  Investigator  
Is this event considered an SAE by the Chief investigator or deputy? 
 
Yes / No 
Is this event considered to be a SUSAR by the Chief investigator /deputy? 
 
Yes / No 
If the answer to SUSAR is yes, do you want to send the report to MHRA/ COREC 
now 
 
Confirmation of date (dd-mm-yyyy) sent to MHRA/COREC 
Confirmation of time  [24 hour clock] sent to MHRA/COREC 
Signature of Chief investigator: 
 
 
Follow-up report required 
 
Yes / No 
Notes 
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AE / SAE Event Categories v1.0 
To be used with SAE form v1 amendment 2 (30. Aug.1009) 
 
Cardiovascular  
Acute coronary syndrome 
(ACS) 
Atrial fibrillation (AF) 
Bradycardia 
Cardiac failure 
Cardiac dysrhythmia 
Chest pain 
Collapse 
Deep vein thrombosis (DVT) 
Hypertension 
Hypotension 
Myocardial infarction (MI) 
Pulmonary embolism (PE) 
Tachycardia 
Unstable angina 
 
 
Central nervous system  
Agitation 
Anxiety 
Cerebral oedema 
Complication of initial stroke 
Dementia 
Depression 
Dysphagia 
Extension of initial stroke 
Haemorrhagic transformation 
(of infarct, HTI) 
Headache 
Intracerebral bleed 
Intracranial/extracerebral bleed 
Recurrent stroke 
Sedation 
Seizure 
Sensory loss 
Transient ischaemic attack 
(TIA) 
Vertigo 
Visual loss 
Weakness 
 
Cutaneous  
Flushing 
Hypersensitivity inc. 
oropharangeal swelling, 
urticaria 
Rash 
 
 
Gastro-intestinal  
Abdominal pain 
Constipation 
Diarrhoea 
Dysphagia 
Gastrointestinal bleed 
Gastrointestinal disturbance 
Incontinence, faecal 
Heartburn 
Hepatitis 
Nausea 
Oral ulceration 
Pancreatitis 
Vomiting 
Weight loss 
 
 
Genito-urinary  
Sexual dysfunction 
Incontinence, urinary 
Renal impairment 
Urinary retention 
Urinary tract infection (UTI) 
 
 
Haematological  
Anaemia 
Leukopenia 
Methaemoglobinaemia 
Thrombocytopenia 
 
Immunological 
Anaphalactoid reaction 
Hypersensitivity 
Miscellaneous 
Acid base disturbance 
Bacteraemia 
Death unattended 
Diaphoresis 
Hyponatraemia 
Hypernatraemia 
Acidosis 
Extracranial bleeding (not GI 
haemorrhage) 
Fall 
Fatigue 
Hyperglycaemia 
Hyperuricaemia 
Infection (not otherwise 
specified) 
Malignancy 
Muscle twitching 
Vascular event (not otherwise 
specified) 
 
 
Respiratory  
Asthma 
Bronchospasm 
Chest infection 
Hypoxia 
Pneumonia 
Pulmonary embolism (PE) 
Shortness of breath 
 
 
Oxygen-related 
Respiratory depression 
Drying of mucous membranes 
 
 
Other (specify) 
______________________ 
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Appendix 3 The health economic questionnaire
 
 
 
 
USE OF RESOURCES QUESTIONNAIRE 
(to be completed by a hospital representative) 
 
1. For the use of routine oxygen supplementation (ROS) for a stroke patient in the 
first 72 hours, what types and grades of staff are required and what is the average 
additional time required per member of staff (over and above all other standard 
care for the patient)? 
 
Use of staff in ROS per treatment group 
 
Staff member (title) 
 
Grade 
Total time (in minutes) allocated per 
intervention 
Treatment group 2 
Night-time ROS for 
72 hours 
Treatment group 3 
Continuous ROS 
for 72 hours 
    
    
 
2. Please give information on the additional equipment required per patient to 
administer routine oxygen supplementation (ROS) for a stroke patient (over 
and above the equipment required in standard care). The average number of 
units mean, on average how many pieces of equipment are required over a 72 
hour period (e.g. 2 oxygen masks, 3 nasal tubes)? We do not need information 
on the amount of oxygen required per patient as we will be able to calculate 
this using trial data. 
 
Equipment 
Use of equipment for ROS in a stroke 
patient 
Average number of units per patient 
Additional 
information to 
assist with 
costing e.g. 
manufacturer (if 
known) 
Treatment group 2 
Night-time ROS for 
72 hours 
Treatment group 3 
Continuous ROS 
for 72 hours 
Oxygen tubing(s)    
Portable oxygen 
cylinder 
   
Nasal tubes    
Oxygen mask 
(Venturi mask, 
MC mask) 
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Other (please 
specify)* 
   
*Please, indicate if there is a piece of equipment normally used by your institution in 
ROS for stroke patients which is not included here 
 
3. Please answer the following questions as accurate as possible: 
 
Questions Answers 
What was the percentage of patients using 
masks? 
 
 
What was the percentage of patients in a 
cannula 
 
 
What was the percentage of patients having 
oxygen from a bottle 
 
 
Do you use dehumidifiers with the cannula? 
 
 
Do you use dehumidifiers with the oxygen 
mask? 
 
 
If a patient had a scan did they have the 
oxygen disconnected during the scan? Or did 
the patient have a scan with the oxygen bottle? 
 
 
How often things get replaced over 3 days? 
 
 
Other comments or further clarification? 
 
 
 
 
4. If you have any further information which you feel may be useful in our 
estimation of ROS costs, please write it here. 
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Thank you for your time 
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Appendix 4 Further details on multiple
imputation of missing European Quality of Life-5
Dimensions, three levels data
We used methods suggested by Royston et al.94 regarding the rule of thumb that the number of cycles forMI should be at least equal to the percentage of incomplete cases of the data set. In addition, when
variables with missing values to be imputed are highly correlated (which was the case in our data) the index
EQ-5D values at 3, 6 and 12 months were highly correlated (–0.7 and more), and more than 10 cycles of MI
were needed for convergence. We used 25 cycles of imputation.
The predictive mean matching approach was used, because the predicted missing value from the
imputation model is replaced with the closest (5) values from the observed complete EQ-5D-3L index.
This method is used when you want to restrict the imputed values to be within the range observed for the
imputed variable (–0.594 and 1 in the case of the EQ-5D index).
The following model was used:
mi impute chained ðpmm, knn(5)) val set 3m (pmm, knn(5)) value set 6m (pmm, knn(5))
value set 12m = age atrand sex patienttreatment nih score patient risks
> core pat randoxig sat, add(25)
Where pmm stands for prediction mean matching, knn refers to the number of closest values from where
a missing figure would be imputed, and add(25) refers to the number of cycles of MI included.
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